WO2005099711A1 - Polycyclic pyrimidines as potassium ion channel modulators - Google Patents

Polycyclic pyrimidines as potassium ion channel modulators Download PDF

Info

Publication number
WO2005099711A1
WO2005099711A1 PCT/US2005/012696 US2005012696W WO2005099711A1 WO 2005099711 A1 WO2005099711 A1 WO 2005099711A1 US 2005012696 W US2005012696 W US 2005012696W WO 2005099711 A1 WO2005099711 A1 WO 2005099711A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
compound
heteroaryl
alkyl
Prior art date
Application number
PCT/US2005/012696
Other languages
French (fr)
Inventor
Xiadong Wang
Kerry Leigh Spear
Alan Bradley Fulp
Darrick Seconi
Takeshi Suzuki
Takahiro Ishii
Ayako Moritomo
Original Assignee
Icagen, Inc.
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icagen, Inc., Astellas Pharma Inc. filed Critical Icagen, Inc.
Priority to EP05749983A priority Critical patent/EP1742634B1/en
Priority to AT05749983T priority patent/ATE485824T1/en
Priority to JP2007508533A priority patent/JP2007532669A/en
Priority to CA002561895A priority patent/CA2561895A1/en
Priority to DE602005024382T priority patent/DE602005024382D1/en
Priority to AU2005232745A priority patent/AU2005232745A1/en
Publication of WO2005099711A1 publication Critical patent/WO2005099711A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • Ion channels are cellular proteins that regulate the flow of ions, including calcium, potassium, sodium and chloride into and out of cells. These channels are present in all human cells and affect such physiological processes as nerve transmission, muscle contraction, cellular secretion, regulation of heartbeat, dilation of arteries, release of insulin, and regulation of renal electrolyte transport.
  • potassium ion channels are the most ubiquitous and diverse, being found in a variety of animal cells such as nervous, muscular, glandular, immune, reproductive, and epithelial tissue. These channels allow the flow of potassium in and/or out of the cell under certain conditions. For example, the outward flow of potassium ions upon opening of these channels makes the interior of the cell more negative, counteracting depolarizing voltages applied to the cell.
  • These channels are regulated, e.g., by calcium sensitivity, voltage-gating, second messengers, extracellular ligands, and ATP-sensitivity.
  • Potassium ion channels are typically formed by four alpha subunits, and can be homomeric (made of identical alpha subunits) or heteromeric (made of two or more distinct types of alpha subunits).
  • certain potassium ion channels (those made from Kv, KQT and Slo or BK subunits) have often been found to contain additional, structurally distinct auxiliary, or beta subunits. These subunits do not form potassium ion channels themselves, but instead they act as auxiliary subunits to modify the functional properties of channels formed by alpha subunits.
  • the Kv beta subunits are cytoplasmic and are known to increase the surface expression of Kv channels and/or modify inactivation kinetics of the channel (Heinemann et al., J. Physiol. 493: 625-633 (1996); Shi et al., Neuron 16(4): 843-852 (1996)).
  • the KQT family beta subunit, minK primarily changes activation kinetics (Sanguinetti et al., Nature 384: 80-83 (1996)).
  • the alpha subunits of potassium ion channels fall into at least 8 families, based on predicted structural and functional similarities (Wei et al, Neuropharmacology 35(7): 805- 829 (1997)).
  • Kv eag-related, and KQT
  • CNG cyclic nucleotides and calcium
  • Small (SK) and intermediate (IK) conductance calcium-activated potassium ion channels possess unit conductances of 2-20 and 20-85 pS, respectively, and are more sensitive to calcium than are BK channels discussed below.
  • Slo or BK family potassium channels have seven transmembrane domains (Meera et al, Proc. Natl Acad. Sci. U.S.A. 94(25): 14066-14071 (1997)) and are gated by both voltage and calcium or pH (Schreiber et al, J. Biol Chem. 273: 3509-3516 (1998)). Slo or BK potassium ion channels are large conductance potassium ion channels found in a wide variety of tissues, both in the central nervous system and periphery.
  • Potassium ion channels show a distinct pharmacological profile. These classes are widely expressed, and their activity hyperpolarizes the membrane potential. Potassium ion channels have been associated with a number of physiological processes, including regulation of heartbeat, dilation of arteries, release of insulin, excitability of nerve cells, and regulation of renal electrolyte transport.
  • potassium ion channels are a therapeutic target in the treatment of a number of diseases including central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety, traumatic brain injury, dysmenorrhea, narcolepsy and motor neuron diseases), as well as targets for neuroprotective agents (e.g., to prevent stroke and the like); as well as disease states such as gastroesophogeal reflux disorder and gastrointestinal hypomotility disorders, irritable bowel syndrome, secretory diarrhea, asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms
  • SK channels have been shown to have distinct pharmacological profiles.
  • the evaluated compounds are structurally related to tricyclic antidepressants and include amitriptyline, carbamazepine, chlorpromazine, cyproheptadine, imipramine, tacrine and trifluperazine.
  • Each of the compounds tested was found to block SK2 channel currents with micromolar affinity.
  • the SK channels are heteromeric complexes that comprise pore- forming o subunits and the calcium binding protein calmodulin (CaM).
  • CaM binds to the SK channel through the CaM-binding domain (CaMBD), which is located in an intracellular region of an ⁇ -subunit close to the pore.
  • CaMBD CaM-binding domain
  • CaMBD CaM-binding domain
  • the present invention provides polycyclic pyrimidines, prodrugs, complexes, and pharmaceutically acceptable salts thereof, which are useful in the treatment of diseases through the modulation of potassium ion flow through potassium ion channels.
  • the potassium ion channel modulator is a compound according to Formula I:
  • a and B are independently substituted or unsubstituted 5- or 6- membered heterocycloalkyl or substituted or unsubstituted 5- or 6- membered heteroaryl.
  • W 1 is I or I .
  • Z 1 is I , ® — N— — N— I , or II .
  • X is a bond, -CH 2 -, or
  • the symbol k is an integer from 1 to 2.
  • R 1 , R 2 , and R 3 are independently H, -OH, -NH 2 , -NO 2 , -SO 2 NH 2 , halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or -NR 7 R 8 .
  • R 7 and R 8 are independently H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 5- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • R 7 and R 8 are optionally joined together with the nitrogen to which they are attached to form a substituted or unsubstituted 5- to 7- membered heterocycloalkyl, or substituted or unsubstituted heteroaryl.
  • R 4 and R 5 are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • each R 1 , R 2 , and/or R 3 is optionally different.
  • R 1 , R 2 , and R 3 may optionally form part of a fused ring system.
  • the present invention provides a method for decreasing ion flow through potassium ion channels in a cell, comprising contacting the cell with a potassium ion channel modulating amount of a modulator of the present invention.
  • the present invention provides a method for treating a disease through the modulation of potassium ion flow through potassium ion channels.
  • the modulators are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety, traumatic brain injury, dysmenorrhea, narcolepsy and motor neuron diseases), and as neuroprotective agents (e.g., to prevent stroke and the like).
  • central or peripheral nervous system disorders e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss
  • the modulators of the invention are also useful in treating disease states such as gastroesophogeal reflux disorder and gastrointestinal hypomotility disorders, irritable bowel syndrome, secretory diarrhea, asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, ischemia, cerebral ischemia, ischemic heart disease, angina pectoris, coronary heart disease, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, arrhythmia, hypertension, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.
  • This method involves administering, to a patient, an effective amount of a modulator of the present invention.
  • the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a modulator of the present invention.
  • Ci-Cio or 1- to 10- membered means one to ten carbons).
  • saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
  • An unsaturated alkyl group is one having one or more double bonds or triple bonds.
  • alkyl groups examples include, but are not limited to, vinyl, 2-propenyl, crotyl, 2- isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(l,4-pentadienyl), ethynyl, 1- and 3- propynyl, 3-butynyl, and the higher homologs and isomers.
  • alkyl unless otherwise noted, is also meant to include those derivatives of alkyl defined in more detail below, such as “heteroalkyl.”
  • Alkyl groups which are limited to hydrocarbon groups are termed "homoalkyl".
  • alkylene by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified, but not limited, by -CH CH 2 CH 2 CH 2 -, and further includes those groups described below as “heteroalkylene.”
  • an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention.
  • a “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
  • alkoxy alkylamino and “alkylthio” (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.
  • heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and at least one heteroatom selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
  • the heteroatom(s) O, N and S and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule.
  • heteroalkylene by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH 2 -CH 2 -S-CH 2 -CH 2 - and -CH 2 -S-CH 2 -CH 2 -NH-CH 2 -.
  • heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula -C(O) 2 R'- represents both -C(O) 2 R'- and -R'C(O) 2 -.
  • cycloalkyl and “heterocycloalkyl”, by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl”, respectively.
  • a cycloalkyl or heterocycloalkyl include saturated and unsaturated ring linkages.
  • a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule.
  • Examples of cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, 1 -cyclohexenyl, 3- cyclohexenyl, cycloheptyl, and the like.
  • heterocycloalkyl examples include, but are not limited to, l-(l,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4- morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2- yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.
  • halo or halogen
  • haloalkyl by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
  • terms such as “haloalkyl,” are meant to include monohaloalkyl and polyhaloalkyl.
  • halo(C ⁇ -C 4 )alkyl is mean to include, but not be limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
  • aryl means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent which can be a single ring or multiple rings (preferably from 1 to 3 rings) which are fused together or linked covalently.
  • heteroaryl refers to aryl groups (or rings) that contain from one to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quatemized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom.
  • Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2- imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5- oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2- furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-pyrimidyl, 4- pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquino
  • aryl when used in combination with other terms (e.g. , aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above.
  • arylalkyl is meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) including those alkyl groups in which a carbon atom (e.g., a methylene group) has been replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(l- naphthyloxy)propyl, and the like).
  • alkyl group e.g., benzyl, phenethyl, pyridylmethyl and the like
  • an oxygen atom e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(l- naphthyl
  • oxo as used herein means an oxygen that is double bonded to a carbon atom.
  • R', R", R'" and R" each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, e.g., aryl substituted with 1 to 3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups.
  • a modulator of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R'" and R"" groups when more than one of these groups is present.
  • R' and R" When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
  • - NR'R is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl.
  • alkyl is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., -CF 3 and -CH 2 CF ) and acyl (e.g., -C(O)CH , - C(O)CF 3 , -C(O)CH 2 OCH 3 , and the like).
  • Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(O)-(CRR') q -U-, wherein T and U are independently -NR-, -O-, -CRR'- or a single bond, and q is an integer of from 0 to 3.
  • two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH ) r -B-, wherein A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O) 2 -, -S(O) 2 NR'- or a single bond, and r is an integer of from 1 to 4.
  • One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
  • two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -(CRR') s -X-(CR"R'")d-, where s and d are independently integers of from 0 to 3, and X is -O-, -NR'-, -S-, -S(O)-, -S(O) 2 -, or -S(O) 2 NR'-.
  • the substituents R, R', R" and R'" are preferably independently selected from hydrogen or substituted or unsubstituted (d- C 6 )alkyl.
  • the term "heteroatom” is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).
  • a "substituent group,” as used herein, means a group selected from the following moieties:
  • a “size-limited substituent” or “size-limited substituent group,” as used herein means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C ⁇ - C 2 o alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2- to 20- membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C -C 8 cycloalkyl, and each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
  • a “lower substituent” or “lower substituent group,” as used herein means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C ⁇ -C 8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 5 - C 7 cycloalkyl, and each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 5 to 7 membered heterocycloalkyl.
  • salts of the active modulators which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the modulators described herein.
  • base addition salts can be obtained by contacting the neutral form of such modulators with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
  • pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
  • acid addition salts can be obtained by contacting the neutral form of such modulators with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
  • Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
  • inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and
  • modulators of the present invention contain both basic and acidic functionalities that allow the modulators to be converted into either base or acid addition salts.
  • the neutral forms of the modulators are preferably regenerated by contacting the salt with a base or acid and isolating the parent modulator in the conventional manner.
  • the parent form of the modulator differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
  • the present invention provides modulators, which are in a prodrug form.
  • Prodrugs of the modulators described herein are those compounds or complexes that readily undergo chemical changes under physiological conditions to provide the modulators of the present invention.
  • prodrugs can be converted to the modulators of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the modulators of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
  • ring as used herein means a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • a ring includes fused ring moities. The number of atoms in a ring are typically defined by the number of members in the ring. For example, a
  • 5- to 7- membered ring means there are 5-7 atoms in the encircling arrangement.
  • the ring optionally includes a heteroatom.
  • the term “5- to 7- membered ring” includes, for example pyridinyl, piperidinyl and thiazolyl rings.
  • poly as used herein means at least 2.
  • a polyvalent metal ion is a metal ion having a valency of at least 2.
  • Moiety refers to the radical of a molecule that is attached to another moiety.
  • Certain modulators of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain modulators of the present invention may exist in multiple crystalline or amorphous forms.
  • modulators of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are encompassed within the scope of the present invention.
  • the modulators of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such modulators.
  • the modulators may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C). All isotopic variations of the modulators of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.
  • the invention provides potassium ion channel modulators that include a pyrimidinyl moiety and a first and a second ring, each of said rings being attached, either directly or through a linker, to the pyrimidinyl moiety.
  • a potassium ion channel modulator of the present invention (“modulator of the present invention”) may be a compound (also referred to herein as a "compound of the present invention”) or metal ion complex (also referred to herein as a "complex of the present invention”), as described below.
  • the potassium ion channel modulator is a compound according to Formula (I):
  • a and B are independently substituted or unsubstituted 5- or 6- membered heterocycloalkyl, or substituted or unsubstituted 5- or 6- membered heteroaryl.
  • W 1 is I or I .
  • Z 1 is I , ⁇ — N— — N— I , or II .
  • X is a bond, -CH 2 -, or
  • the symbols s and t are independently integers from 1 to 4.
  • A is a 5- membered heterocycloalkyl or 5- membered heteroaryl
  • s is an integer from 1 to 3
  • A is a 6- membered heterocycloalkyl or 6- membered heteroaryl
  • s is an integer from 1 to 4.
  • B is a 5- membered heterocycloalkyl or 5- membered heteroaryl
  • t is an integer from 1 to 3
  • B is a 6- membered heterocycloalkyl or 6- membered heteroaryl
  • t is an integer from 1 to 4.
  • the symbol k is an integer from 1 to 2.
  • R 1 , R 2 , and R 3 are independently H, -OH, -NH 2 , -NO 2 , -SO 2 NH 2 , halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or -NR 7 R 8 .
  • R 7 and R 8 are independently H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 5- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • R 7 and R 8 are optionally joined together with the nitrogen to which they are attached to form a substituted or unsubstituted 5- to 7- membered heterocycloalkyl, or substituted or unsubstituted heteroaryl.
  • R 4 and R 5 are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • each R 1 , R 2 , and/or R 3 group is optionally different.
  • each R 1 , R 2 , and/or R 3 group is optionally different.
  • R 1 , R 2 , and R 3 may optionally form part of a fused ring system.
  • R 1 groups are optionally joined together with the atoms to which they are attached to form a substituted or unsubstituted 5- to 7- membered ring;
  • two R 2 groups are optionally joined together with the atoms to which they are attached to form a substituted or unsubstituted 5- to 7- membered ring;
  • two R groups are optionally joined together with the atoms to which they are attached to form a substituted or unsubstituted 5- to 7- membered ring.
  • A is substituted or unsubstituted heteroaryl.
  • A may also be substituted or unsubstituted pyridinyl.
  • A is
  • R 1 and s are as defined above in the description of Formula (I).
  • R 1 is selected from H, halogen, -NH 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 5- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • A may also be R 1 is as described above in the discussion of Formula (I) of Formula (III).
  • R 1 is halogen, or substituted or unsubstituted alkyl.
  • R 1 is CI or unsubstituted alkyl
  • A may
  • B is substituted or unsubstituted heteroaryl.
  • B may also be substituted or unsubstituted pyridinyl.
  • B is
  • R and t are as defined above in the description of Formula (I).
  • R 3 is H, -NH 2 , -NO , halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • R 3 is CI or -NR 7 R 8 .
  • R 3 is -NH 2 , -N(CH 3 ) 2 ,
  • B is or R is as defined above in the description of Formula (I) or Formula (II). In other embodiments, R is substituted or
  • R 1 , R 2 , and R 3 may independently be H, -NH 2 , -NO 2 , halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or -NR 7 R 8 .
  • R 1 may be H, substituted or unsubstituted (Ci-Cio) alkyl, substituted or unsubstituted 2- to 10- membered heteroalkyl, or substituted or unsubstituted aryl.
  • R 1 may also be H, methyl, -NH 2 , or unsubstituted phenyl.
  • R 2 may be H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, or substituted or unsubstituted aryl.
  • R 2 may also be H, CI, methyl, -OCH 3 , or unsubstituted pyridinyl. In some embodiments, R 2 is H or -OCH 3 .
  • R 3 may be H, -NH 2 , -NO 2 , halogen, substituted or unsubstituted (Ci-Cio) alkyl, substituted or unsubstituted 2- to 10- membered heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • R may also be H, -NH , -NO , CI, Br, F, methyl, phenyl, fluorophenyl, -CF 3 , -OCH 3 , dimethylamino, unsubstituted piperidine, p- methyl morpholino, unsubstituted pyrrolidinonyl, unsubstituted 2-thiophenyl, unsubstituted
  • R 3 is CI or -NR 7 R 8 , where R 7 and R 8 are as defined above.
  • R ⁇ J > m-ay also be selected , f_rom_ R_ J3 i,s C GuideI, -N ._H . 2 , -N « (,C ThreadH . 3 ) . 2 , N , . 0 Strukturr
  • X is a bond.
  • k is 2.
  • R 2 is H or -OCH 3 .
  • Y is NH.
  • t is 1.
  • B is
  • R is as defined above in the description of Formula (II).
  • B is as defined above in the description of Formula (II).
  • Y may also represent a bond.
  • k is 1.
  • R is H.
  • X may be NH.
  • A is
  • R 1 and s are as defined above in the description of Formula (III).
  • each substituted moiety described above for the compounds of the present invention is substituted with at least one substituent group.
  • substituent group is defined in detail above in the "Abbreviations and Definitions" section. More specifically, in some embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl described above are substituted with at least one substituent group. Each substituent group is optionally different. In other embodiments, at least one or all of these groups are substituted with at least one size-limited substituent group.
  • each substituted or unsubstituted alkyl is a substituted or unsubstituted C ⁇ -C 2 n alkyl
  • each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2- to 20- membered heteroalkyl.
  • each substituted or unsubstituted alkyl is a substituted or unsubstituted C ⁇ -C 8 alkyl
  • each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2- to 8- membered heteroalkyl.
  • the present invention provides a metal complex modulator, comprising a polyvalent metal ion (e.g. iron, zinc, copper, cobalt, manganese, and nickel) and a polydentate component of a metal ion chelator.
  • the polydentate component is a compound of the present invention (e.g. a compound of Formulae (I), (II), or (III)).
  • the metal complexes of the present invention are potassium ion channel modulators.
  • the metal complex modulator has the structure
  • M is a polyvalent metal ion (e.g. iron, zinc, copper, cobalt, manganese, and nickel).
  • W 1 , Z 1 , R 1 , R 2 , R 3 , X, Y, s, k, t, A, and B are as defined above in the description of the compound of Formula (I).
  • compounds of the invention that function as poly- or multi-valent species, including, for example, species such as dimers, trimers, tetramers and higher homologs of the compounds of the invention or reactive analogues thereof.
  • the poly- and multi-valent species can be assembled from a single species or more than one species of the invention.
  • a dimeric construct can be "homo-dimeric" or "heterodimeric.”
  • poly- and multi-valent constructs in which a compound of the invention or reactive analogues thereof are attached to an oligomeric or polymeric framework e.g., polylysine, dextran, hydroxyethyl starch and the like
  • the framework is preferably polyfunctional (i.e. having an array of reactive sites for attaching compounds of the invention).
  • the framework can be derivatized with a single species of the invention or more than one species of the invention.
  • modulators of the present invention illustrate methods of preparing the modulators of the present invention. These methods are not limited to producing the compounds shown, but can be used to prepare a variety of modulators such as the compounds and complexes described above.
  • the modulators of the invention can also be produced by methods not explicitly illustrated in the schemes but are well within the skill of one in the art.
  • the modulators can be prepared using readily available starting materials or known intermediates.
  • the symbol Y is independently selected from CH 2 , N, S, and O.
  • the symbol D is independently selected from H, -OH, -NH 2 , -NO 2 , -SO 2 NH 2 , halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
  • the symbol p is an integer independently selected from 1-5.
  • the symbol q is an integer independently selected from 0-5.
  • the substituents of the invention comprise amino-substituted heteroaryl moieties as shown in Schemes 1-6.
  • amino substituents can be added to the heteroaryl moieties in the following manner.
  • the substituents of the invention comprise halo-substituted heteroaryl moieties as shown in Scheme 7.
  • the substituents of the invention comprise stannyl- substituted heteroaryl moieties as shown in Scheme 8.
  • Amino-substituted heteroaryl moieties can be added to a pyrimidine compound of the invention through the methods outlined in Scheme 11.
  • the pyrimidine ring can be formed by a method outlined in Scheme 15.
  • Compound 27 is reacted with stannyl derivative 14 in order to produce compound 28.
  • Compound 28 is then reacted with compound 2 or 8.
  • the product is a bis-substituted pyrimidine 29.
  • the compounds of the invention also include metal complexes. These metal complexes comprise a polyvalent metal ion and a pyrimidinyl compound of the invention.
  • the polyvalent metal ion can be a transition metal.
  • the polyvalent metal ion is a member selected from iron, zinc, copper, cobalt, manganese, and nickel.
  • SK monomers as well as SK alleles and polymorphic variants are subunits of potassium ion channels.
  • the activity of a potassium ion channel comprising SK subunits can be assessed using a variety of in vitro and in vivo assays, e.g., measuring current, measuring membrane potential, measuring ion flow, e.g. , potassium or rubidium, measuring potassium concentration, measuring second messengers and transcription levels, using potassium-dependent yeast growth assays, and using e.g., voltage-sensitive dyes, radioactive tracers, and patchClamp electrophysiology.
  • such assays can be used to test for inhibitors and activators of channels comprising SK.
  • the SK family of channels is implicated in a number of disorders that are targets for a therapeutic or prophylactic regimen, which functions by blockade or inhibition of one or more members of the SK channel family.
  • the modulators and methods of the invention are useful to treat central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety, traumatic brain injury, dysmenorrhea, narcolepsy and motor neuron diseases).
  • central or peripheral nervous system disorders e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety, traumatic brain injury, dysmenorrhea, n
  • the modulators of the invention are also useful in treating disease states such as gastroesophogeal reflux disorder and gastrointestinal hypomotility disorders, irritable bowel syndrome, secretory diarrhea, asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, ischemia, cerebral ischemia, ischemic heart disease, angina pectoris, coronary heart disease, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, arrhythmia, hypertension, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.
  • disease states such as gastroesophogeal reflux disorder and gastrointestinal hypomotility disorders, irritable bowel syndrome, secretory diarrhea, asthma, cystic
  • Modulators of the potassium ion channels are tested using biologically active SK, either recombinant or naturally occurring, or by using native cells, like cells from the nervous system expressing an SK channel.
  • SK channels can be isolated, co-expressed or expressed in a cell, or expressed in a membrane derived from a cell.
  • SK is expressed alone to form a homomeric potassium ion channel or is co-expressed with a second subunit (e.g., another SK family member) so as to form a heteromeric potassium ion channel. Modulation is tested using one of the in vitro or in vivo assays described above.
  • Samples or assays that are treated with a potential potassium ion channel inhibitor or activator are compared to control samples without the test modulator, to examine the extent of modulation.
  • Control samples (untreated with activators or inhibitors) are assigned a relative potassium ion channel activity value of 100.
  • Inhibition of channels comprising SK is achieved when the potassium ion channel activity value relative to the control is less than 70%, preferably less than 40% and still more preferably, less than 30%.
  • Modulators that decrease the flow of ions will cause a detectable decrease in the ion current density by decreasing the probability of a channel comprising SK being open, by decreasing conductance through the channel, and decreasing the number or expression of channels.
  • Changes in ion flow may be assessed by determining changes in polarization (i.e., electrical potential) of the cell or membrane expressing the potassium ion channel.
  • a preferred means to determine changes in cellular polarization is by measuring changes in current or voltage with the voltageClamp and patchClamp techniques, using the "cell- attached” mode, the "inside-out” mode, the “outside-out” mode, the “perforated cell” mode, the “one or two electrode” mode, or the “whole cell” mode (see, e.g., Ackerman et al, New Engl J. Med. 336: 1575-1595 (1997)).
  • Assays for modulators capable of inhibiting or increasing potassium flow through the channel proteins can be performed by application of the modulators to a bath solution in contact with and comprising cells having a channel of the present invention (see, e.g., Blatz et al, Nature 323: 718-720 (1986); Park, J. Physiol. 481: 555-570 (1994)).
  • the modulators to be tested are present in the range from about 1 pM to about 100 mM, preferably from about 1 pM to about 1 ⁇ M.
  • the effects of the test modulators upon the function of the channels can be measured by changes in the electrical currents or ionic flow or by the consequences of changes in currents and flow. Changes in electrical current or ionic flow are measured by either increases or decreases in flow of ions such as potassium or rubidium ions.
  • the cations can be measured in a variety of standard ways. They can be measured directly by concentration changes of the ions or indirectly by membrane potential or by radio-labeling of the ions. Consequences of the test modulator on ion flow can be quite varied. Accordingly, any suitable physiological change can be used to assess the influence of a test modulator on the channels of this invention.
  • the effects of a test modulator can be measured by a toxin-binding assay.
  • transmitter release e.g., dopamine
  • hormone release e.g., insulin
  • transcriptional changes to both known and uncharacterized genetic markers e.g., northern blots
  • cell volume changes e.g., in red blood cells
  • immunoresponses e.g., T cell activation
  • changes in cell metabolism such as cell growth or pH changes
  • changes in intracellular second messengers such as calcium, or cyclic nucleotides.
  • the present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a modulator of the present invention (e.g. a compound of the present invention or a complex of the present invention).
  • a modulator of the present invention e.g. a compound of the present invention or a complex of the present invention.
  • the modulators of the present invention can be prepared and administered in a wide variety of oral, parenteral and topical dosage forms.
  • the modulators of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally.
  • the modulators described herein can be administered by inhalation, for example, intranasally.
  • the modulators of the present invention can be administered transdermally.
  • the present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and either a modulator, or a pharmaceutically acceptable salt of a modulator.
  • pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances, which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from 5% or 10% to 70% of the active modulator.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term "preparation” is intended to include the formulation of the active modulator with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included.
  • Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
  • the active component is dispersed homogeneously therein, as by stirring.
  • the molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
  • Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions.
  • liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
  • liquid forms include solutions, suspensions, and emulsions.
  • These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the pharmaceutical preparation is preferably in unit dosage form.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 10000 mg, more typically 1.0 mg to 1000 mg, most typically 10 mg to 500 mg, according to the particular application and the potency of the active component.
  • composition can, if desired, also contain other compatible therapeutic agents.
  • the present invention provides a method for decreasing ion flow through potassium ion channels in a cell, comprising contacting the cell with a potassium ion channel modulating amount of a modulator of the present invention.
  • the potassium ion channels comprise at least one SK subunit.
  • the methods provided in this aspect of the invention are useful in the therapy of conditions mediated through potassium ion flow, as well as for the diagnosis of conditions that can be treated by decreasing ion flow through potassium ion channels. Additionally the methods are useful for determining if a patient will be responsive to therapeutic agents which act by modulating potassium ion channels.
  • a patient's cell sample can be obtained and contacted with a potassium ion channel modulator described above and the ion flow can be measured relative to a cell's ion flow in the absence of the modulator. A decrease in ion flow will typically indicate that the patient will be responsive to a therapeutic regiment of the modulator.
  • the present invention provides a method for treating a disease through the modulation of potassium ion flow through potassium ion channels.
  • the modulation may be activation or inhibition of the potassium ion flow.
  • the modulators of the present invention may be inhibitors of potassium ion flow through potassium ion channels (i.e. decrease the flow relative to the absence of the modulator) or activators of potassium ion flow through potassium ion channels (i.e. increase the flow relative to the absence of the modulator).
  • the modulators are useful in the treatment of central or peripheral nervous system disorders (e.g. , migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety, traumatic brain injury, dysmenorrhea, narcolepsy and motor neuron diseases), and as neuroprotective agents (e.g., to prevent stroke and the like).
  • central or peripheral nervous system disorders e.g. , migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, age-related memory loss, learning
  • the modulators of the invention are also useful in treating disease states such as gastroesophogeal reflux disorder and gastrointestinal hypomotility disorders, irritable bowel syndrome, secretory diarrhea, asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, ischemia, cerebral ischemia, ischemic heart disease, angina pectoris, coronary heart disease, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, arrhythmia, hypertension, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.
  • This method involves administering, to a patient, an effective amount (e.g. a therapeutically effective amount) of a modulator of the present invention (a
  • the present invention provides a method of decreasing ion flow through potassium ion channels in a cell.
  • the method includes contacting the cell with a potassium ion channel-modulating amount of a modulator of the present invention.
  • the potassium ion channel includes at least one SK subunit.
  • the cell may be isolated or form part of a organ or organism.
  • the modulators provided herein find therapeutic utility via modulation of potassium ion channels in the treatment of diseases or conditions.
  • the potassium ion channels that are typically modulated are described herein. As noted above, these channels may include homomultimers and heteromultimers.
  • the modulators utilized in the pharmaceutical method of the invention are administered at the initial dosage of about 0.001 mg/kg to about 1000 mg/kg daily.
  • a daily dose range of about 0.1 mg kg to about 100 mg/kg is more typical.
  • the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the modulator being employed. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the modulator. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day.
  • temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, "rt,” or “RT,” (typically a range of from about 18-25 °C); evaporation of solvent was carried out using a rotary evaporator under reduced pressure (typically, 4.5-30 mm Hg) with a bath temperature of up to 60 °C; the course of reactions was typically followed by thin layer chromatography (TLC) and reaction times are provided for illustration only; melting points are uncorrected; products exhibited satisfactory ' H-NMR and/or microanalytical data; yields are provided for illustration only; and the following conventional abbreviations are also used: mp (melting point), L (liter(s)), mL (milliliters), mmol (millimoles), g (grams), mg (milligrams), min (minutes), and h (hours).
  • EXAMPLE 20 20.1 Assay for Compound Activity Towards hSK Channels [0252] Cells expressing small conductance, calcium activated potassium channels, such as SK-like channels were loaded with 86 Rb + by culture in media containing 86 RbCl. Following loading, the culture media was removed and the cells were washed in EBSS to remove residual traces of 86 Rb + . Cells were preincubated with the drug (0.01 to 30 ⁇ M in EBSS) and then 86 Rb + efflux was stimulated by exposing cells to EBSS solution supplemented with a calcium ionophore, such as ionomycin, in the continued presence of the drug.
  • a calcium ionophore such as ionomycin
  • + indicates 30 ⁇ M>IC50>5.0 ⁇ M; ++ indicates 5.0 ⁇ M>IC50>1.0 ⁇ M; +++ indicates 1.0 ⁇ M>IC50>0.1 ⁇ M; ++++ indicates 0.1 ⁇ M>IC50>0.0 ⁇ M.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)

Abstract

The present invention provides a genus of polycyclic pyrimidines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.

Description

POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims the benefit of United States Provisional Patent Application No. 60/561,990, filed April 13, 2004, which is incorporated herein by reference in its entirety for all purposes.
BACKGROUND OF THE INVENTION
[0002] Ion channels are cellular proteins that regulate the flow of ions, including calcium, potassium, sodium and chloride into and out of cells. These channels are present in all human cells and affect such physiological processes as nerve transmission, muscle contraction, cellular secretion, regulation of heartbeat, dilation of arteries, release of insulin, and regulation of renal electrolyte transport. Among the ion channels, potassium ion channels are the most ubiquitous and diverse, being found in a variety of animal cells such as nervous, muscular, glandular, immune, reproductive, and epithelial tissue. These channels allow the flow of potassium in and/or out of the cell under certain conditions. For example, the outward flow of potassium ions upon opening of these channels makes the interior of the cell more negative, counteracting depolarizing voltages applied to the cell. These channels are regulated, e.g., by calcium sensitivity, voltage-gating, second messengers, extracellular ligands, and ATP-sensitivity.
[0003] Potassium ion channels are typically formed by four alpha subunits, and can be homomeric (made of identical alpha subunits) or heteromeric (made of two or more distinct types of alpha subunits). In addition, certain potassium ion channels (those made from Kv, KQT and Slo or BK subunits) have often been found to contain additional, structurally distinct auxiliary, or beta subunits. These subunits do not form potassium ion channels themselves, but instead they act as auxiliary subunits to modify the functional properties of channels formed by alpha subunits. For example, the Kv beta subunits are cytoplasmic and are known to increase the surface expression of Kv channels and/or modify inactivation kinetics of the channel (Heinemann et al., J. Physiol. 493: 625-633 (1996); Shi et al., Neuron 16(4): 843-852 (1996)). In another example, the KQT family beta subunit, minK, primarily changes activation kinetics (Sanguinetti et al., Nature 384: 80-83 (1996)). [0004] The alpha subunits of potassium ion channels fall into at least 8 families, based on predicted structural and functional similarities (Wei et al, Neuropharmacology 35(7): 805- 829 (1997)). Three of these families (Kv, eag-related, and KQT) share a common motif of six transmembrane domains and are primarily gated by voltage. Two other families, CNG and SK/IK, also contain this motif but are gated by cyclic nucleotides and calcium, respectively. Small (SK) and intermediate (IK) conductance calcium-activated potassium ion channels possess unit conductances of 2-20 and 20-85 pS, respectively, and are more sensitive to calcium than are BK channels discussed below. For a review of calcium- activated potassium channels see Latorre et al, Ann. Rev. Phys. 51: 385-399 (1989).
[0005] Three other families of potassium channel alpha subunits have distinct patterns of transmembrane domains. Slo or BK family potassium channels have seven transmembrane domains (Meera et al, Proc. Natl Acad. Sci. U.S.A. 94(25): 14066-14071 (1997)) and are gated by both voltage and calcium or pH (Schreiber et al, J. Biol Chem. 273: 3509-3516 (1998)). Slo or BK potassium ion channels are large conductance potassium ion channels found in a wide variety of tissues, both in the central nervous system and periphery. These channels are gated by the concerted actions of internal calcium ions and membrane potential, and have a unit conductance between 100 and 220 pS. They play a key role in the regulation of processes such as neuronal integration, muscular contraction and hormone secretion. They may also be involved in processes such as lymphocyte differentiation and cell proliferation, spermatocyte differentiation and sperm motility. Members of the BK (Atkinson et al, Science 253: 551-555 (1991); Adelman et al, Neuron 9: 209-216 (1992); Butler, Science 261: 221-224 (1993)) subfamily have been cloned and expressed in heterologous cell types where they recapitulate the fundamental properties of their native counterparts. Finally, the inward rectifier potassium channels (Kir), belong to a structural family containing two transmembrane domains, and an eighth functionally diverse family (TP, or "two-pore") contains two tandem repeats of this inward rectifier motif.
[0006] Each type of potassium ion channel shows a distinct pharmacological profile. These classes are widely expressed, and their activity hyperpolarizes the membrane potential. Potassium ion channels have been associated with a number of physiological processes, including regulation of heartbeat, dilation of arteries, release of insulin, excitability of nerve cells, and regulation of renal electrolyte transport. Moreover, studies have indicated that potassium ion channels are a therapeutic target in the treatment of a number of diseases including central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety, traumatic brain injury, dysmenorrhea, narcolepsy and motor neuron diseases), as well as targets for neuroprotective agents (e.g., to prevent stroke and the like); as well as disease states such as gastroesophogeal reflux disorder and gastrointestinal hypomotility disorders, irritable bowel syndrome, secretory diarrhea, asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, ischemia, cerebral ischemia, ischemic heart disease, angina pectoris, coronary heart disease, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, arrhythmia, hypertension, myotonic muscle dystrophia, xerostomia, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.
[0007] Specifically, SK channels have been shown to have distinct pharmacological profiles. For example, using patch clamp techniques, the effects of eight clinically relevant psychoactive compounds on SK2 subtype channels were investigated (Dreixler et al, Eur. J. Pharmacol. 401: 1-7 (2000)). The evaluated compounds are structurally related to tricyclic antidepressants and include amitriptyline, carbamazepine, chlorpromazine, cyproheptadine, imipramine, tacrine and trifluperazine. Each of the compounds tested was found to block SK2 channel currents with micromolar affinity. A number of neuromuscular inhibiting agents exist that affect SK channels, e.g. apamin, atracurium, pancuronium and tubocurarine (Shah et al, BrJ Pharmacol 129: 627-30 (2000)).
[0008] Moreover, patch clamp techniques have also been used to study the effect of the centrally acting muscle relaxant chlorzoxazone and three structurally related compounds, 1- ethyl-2-benzimidazolinone (1-EBIO), zoxazolamine, and l,3-dihydro-l-[2-hydroxy-5- (trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one (NS 1619) on recombinant rat brain SK2 channels (rSK2 channels) expressed in HEK293 mammalian cells (Cao et al, J Pharmacol. Exp. Ther. 296: 683-689 (2001)). When applied externally, chlorzoxazone, 1-EBIO, and zoxazolamine activated rSK2 channel currents in cells dialyzed with a nominally calcium-free intracellular solution. [0009] The effects of metal cations on the activation of recombinant human SK4 (also known as hIKl or hKCa4) channels has also been studied (Cao and Houamed, FEBS Lett. 446: 137-41 (1999)). The ion channels were expressed in HEK 293 cells and tested using patch clamp recording. Of the nine metals tested, cobalt, iron, magnesium, and zinc did not activate the SK4 channels when applied to the inside of SK4 channel-expressing membrane patches. Barium, cadmium, calcium, lead, and strontium activated SK4 channels in a concentration-dependent manner. Calcium was the most potent metal, followed by lead, cadmium, strontium, and barium.
[0010] The SK channels are heteromeric complexes that comprise pore- forming o subunits and the calcium binding protein calmodulin (CaM). CaM binds to the SK channel through the CaM-binding domain (CaMBD), which is located in an intracellular region of an α-subunit close to the pore. Based on a recently published crystal structure, calcium binding to the N-lobe of the CaM proteins on each of the four subunits initiates a structural change that allows a hydrophobic portion of the CaM protein to interact with a CaMBD on an adjacent subunit. As each N-lobe on an adjacent subunit grabs the other CaMBD C- terminal region, a rotary force is thought to be created between them which would drive open the channel.
[0011] New classes of compounds that act to modulate the opening of potassium ion channels would represent a significant advance in the art and provide the opportunity to develop treatment modalities for numerous diseases associated with these channels. The present invention provides a new class of potassium ion channel modulators and methods of using the modulators.
BRIEF SUMMARY OF THE INVENTION
[0012] The present invention provides polycyclic pyrimidines, prodrugs, complexes, and pharmaceutically acceptable salts thereof, which are useful in the treatment of diseases through the modulation of potassium ion flow through potassium ion channels.
[0013] In a first aspect, the potassium ion channel modulator is a compound according to Formula I:
Figure imgf000006_0001
In Formula (I), A and B are independently substituted or unsubstituted 5- or 6- membered heterocycloalkyl or substituted or unsubstituted 5- or 6- membered heteroaryl. The symbol — C= — N— — C=
W1 is I or I . W2 is -CH=, -NH-, -N=, or -O-. The symbol Z1 is I , ® — N— — N— I , or II . Z2 is -CH=, -NH-, -N=, or -O-. The symbol X is a bond, -CH2-, or
-NR4-. Y is a bond, -CH=N-NH-, -NH-CH2-, or -NR5-.
[0014] The symbols s and t are independently integers from 1 to 4.
[0015] The symbol k is an integer from 1 to 2.
[0016] R1, R2, and R3 are independently H, -OH, -NH2, -NO2, -SO2NH2, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or -NR7R8.
[0017] R7 and R8 are independently H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 5- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. R7 and R8 are optionally joined together with the nitrogen to which they are attached to form a substituted or unsubstituted 5- to 7- membered heterocycloalkyl, or substituted or unsubstituted heteroaryl.
[0018] R4 and R5 are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0019] Where a plurality of R1, R2, and/or R3 groups are present, each R1, R2, and/or R3 is optionally different.
[0020] R1 , R2, and R3 may optionally form part of a fused ring system. [0021] In a second aspect, the present invention provides a method for decreasing ion flow through potassium ion channels in a cell, comprising contacting the cell with a potassium ion channel modulating amount of a modulator of the present invention.
[0022] In a third aspect, the present invention provides a method for treating a disease through the modulation of potassium ion flow through potassium ion channels. The modulators are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety, traumatic brain injury, dysmenorrhea, narcolepsy and motor neuron diseases), and as neuroprotective agents (e.g., to prevent stroke and the like). The modulators of the invention are also useful in treating disease states such as gastroesophogeal reflux disorder and gastrointestinal hypomotility disorders, irritable bowel syndrome, secretory diarrhea, asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, ischemia, cerebral ischemia, ischemic heart disease, angina pectoris, coronary heart disease, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, arrhythmia, hypertension, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression. This method involves administering, to a patient, an effective amount of a modulator of the present invention.
[0023] In a fourth aspect, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a modulator of the present invention.
[0024] These and other aspects and embodiments of the invention will be apparent from the detailed description that follows.
DETAILED DESCRIPTION OF THE INVENTION
I. Abbreviations and Definitions
[0025] The abbreviations used herein have their conventional meaning within the chemical and biological arts. [0026] Where moieties are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., -CH O- is equivalent to -OCH2-. [0027] The term "alkyl," by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e. Ci-Cio or 1- to 10- membered means one to ten carbons). Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2- isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(l,4-pentadienyl), ethynyl, 1- and 3- propynyl, 3-butynyl, and the higher homologs and isomers. The term "alkyl," unless otherwise noted, is also meant to include those derivatives of alkyl defined in more detail below, such as "heteroalkyl." Alkyl groups which are limited to hydrocarbon groups are termed "homoalkyl".
[0028] The term "alkylene" by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified, but not limited, by -CH CH2CH2CH2-, and further includes those groups described below as "heteroalkylene." Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms. [0029] The terms "alkoxy," "alkylamino" and "alkylthio" (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively. [0030] The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and at least one heteroatom selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Examples include, but are not limited to, -CH2-CH2-O-CH3, -CH2-C(=O)- CH3, -CH2-CH2-CH2-C(=O)-O-C(CH3)-CH3, -CH2-CH2-CH2-C(=O)-N-CH(CH3), -CH2- CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2,-S(O)-CH3, - CH2-CH2-S(O)2-CH3, -CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N-OCH3, and -CH=CH- N(CH3)-CH3. Up to two heteroatoms may be consecutive, such as, for example, -CH2-NH- OCH3 and -CH2-O-Si(CH3)3. Similarly, the term "heteroalkylene" by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH2-CH2-S-CH2-CH2- and -CH2-S-CH2-CH2-NH-CH2-. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula -C(O)2R'- represents both -C(O)2R'- and -R'C(O)2-.
[0031] The terms "cycloalkyl" and "heterocycloalkyl", by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of "alkyl" and "heteroalkyl", respectively. Thus, a cycloalkyl or heterocycloalkyl include saturated and unsaturated ring linkages. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, 1 -cyclohexenyl, 3- cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, l-(l,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4- morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2- yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. [0032] The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "haloalkyl," are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "halo(Cι-C4)alkyl" is mean to include, but not be limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like. [0033] The term "aryl" means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent which can be a single ring or multiple rings (preferably from 1 to 3 rings) which are fused together or linked covalently. The term "heteroaryl" refers to aryl groups (or rings) that contain from one to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quatemized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2- imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5- oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2- furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-pyrimidyl, 4- pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5- isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.
[0034] For brevity, the term "aryl" when used in combination with other terms (e.g. , aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above. Thus, the term "arylalkyl" is meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) including those alkyl groups in which a carbon atom (e.g., a methylene group) has been replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(l- naphthyloxy)propyl, and the like).
[0035] The term "oxo" as used herein means an oxygen that is double bonded to a carbon atom.
[0036] Each of the above terms (e.g., "alkyl," "heteroalkyl," "aryl" and "heteroaryl") are meant to include both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below. [0037] Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to: -OR', =O, =NR', =N-OR', -NR'R", -SR', -halogen, -SiR'R"R"', -OC(O)R', -C(O)R', -CO2R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R'", -NR"C(O)2R', -NR-C(NR'R"R'")=NR"", -NR-C(NR'R")=NR'", -S(O)R', -S(O)2R', -S(O)2NR'R", -NRSO2R', -CN and -NO2 in a number ranging from zero to (2m'+l), where m' is the total number of carbon atoms in such radical. R', R", R'" and R"" each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, e.g., aryl substituted with 1 to 3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups. When a modulator of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R'" and R"" groups when more than one of these groups is present. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, - NR'R" is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term "alkyl" is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., -CF3 and -CH2CF ) and acyl (e.g., -C(O)CH , - C(O)CF3, -C(O)CH2OCH3, and the like).
[0038] Similar to the substituents described for the alkyl radical, substituents for the aryl and heteroaryl groups are varied and are selected from, for example: halogen, -OR', =O, =NR\ =N-OR', -NR'R", -SR', -halogen, -SiR'R"R"', -OC(O)R', -C(0)R\ -CO2R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R'", -NR"C(O)2R', -NR-C(NR'R"R"')=NR"", -NR-C(NR'R")=NR'", -S(O)R', -S(O)2R', -S(O)2NR'R", -NRSO2R', -CN and -NO2, -R', -N3, -CH(Ph)2, fluoro(Cι-C4)alkoxy, and fluoro(Cι- C4)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R", R'" and R"" are preferably independently selected from hydrogen, alkyl, heteroalkyl, aryl and heteroaryl. When a modulator of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R'" and R"" groups when more than one of these groups is present.
[0039] Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(O)-(CRR')q-U-, wherein T and U are independently -NR-, -O-, -CRR'- or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH )r-B-, wherein A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O)2-, -S(O)2NR'- or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -(CRR')s-X-(CR"R'")d-, where s and d are independently integers of from 0 to 3, and X is -O-, -NR'-, -S-, -S(O)-, -S(O)2-, or -S(O)2NR'-. The substituents R, R', R" and R'" are preferably independently selected from hydrogen or substituted or unsubstituted (d- C6)alkyl. [0040] As used herein, the term "heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).
[0041] A "substituent group," as used herein, means a group selected from the following moieties:
[0042] (A) -OH, -NH2, -SH, -CN, -CF3, oxy, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and [0043] (B) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, substituted with at least one substituent selected from: [0044] (i) oxy, -OH, -NH2, -SH, -CN, -CF3, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and [0045] (ii) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, substituted with at least one substituent selected from: [0046] (a) oxy, -OH, -NH2, -SH, -CN, -CF3, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, and [0047] (b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, substituted with at least one substituent selected from oxy, -OH, -NH2, -SH, -CN, -CF3, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, and unsubstituted heteroaryl. [0048] A "size-limited substituent" or "size-limited substituent group," as used herein means a group selected from all of the substituents described above for a "substituent group," wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C\- C2o alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2- to 20- membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C -C8 cycloalkyl, and each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
[0049] A "lower substituent" or "lower substituent group," as used herein means a group selected from all of the substituents described above for a "substituent group," wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted Cι-C8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C5- C7 cycloalkyl, and each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 5 to 7 membered heterocycloalkyl.
[0050] The term "pharmaceutically acceptable salts" is meant to include salts of the active modulators which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the modulators described herein. When modulators of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such modulators with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When modulators of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such modulators with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al. , "Pharmaceutical Salts", Journal of Pharmaceutical Science 66: 1-19 (1977)). Certain specific modulators of the present invention contain both basic and acidic functionalities that allow the modulators to be converted into either base or acid addition salts. [0051] The neutral forms of the modulators are preferably regenerated by contacting the salt with a base or acid and isolating the parent modulator in the conventional manner. The parent form of the modulator differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
[0052] In addition to salt forms, the present invention provides modulators, which are in a prodrug form. Prodrugs of the modulators described herein are those compounds or complexes that readily undergo chemical changes under physiological conditions to provide the modulators of the present invention. Additionally, prodrugs can be converted to the modulators of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the modulators of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
[0053] The term "ring" as used herein means a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. A ring includes fused ring moities. The number of atoms in a ring are typically defined by the number of members in the ring. For example, a
"5- to 7- membered ring" means there are 5-7 atoms in the encircling arrangement. The ring optionally includes a heteroatom. Thus, the term "5- to 7- membered ring" includes, for example pyridinyl, piperidinyl and thiazolyl rings.
[0054] The term "poly" as used herein means at least 2. For example, a polyvalent metal ion is a metal ion having a valency of at least 2.
[0055] "Moiety" refers to the radical of a molecule that is attached to another moiety.
[0056] The symbol °-π-r^ , whether utilized as a bond or displayed perpendicular to a bond indicates the point at which the displayed moiety is attached to the remainder of the molecule.
[0057] Certain modulators of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain modulators of the present invention may exist in multiple crystalline or amorphous forms.
In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
[0058] Certain modulators of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are encompassed within the scope of the present invention. [0059] The modulators of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such modulators. For example, the modulators may be radiolabeled with radioactive isotopes, such as for example tritium (3H), iodine-125 (125I) or carbon-14 (14C). All isotopic variations of the modulators of the present invention, whether radioactive or not, are encompassed within the scope of the present invention. II. Potassium Ion Channel Modulators
[0060] The invention provides potassium ion channel modulators that include a pyrimidinyl moiety and a first and a second ring, each of said rings being attached, either directly or through a linker, to the pyrimidinyl moiety. A potassium ion channel modulator of the present invention ("modulator of the present invention") may be a compound (also referred to herein as a "compound of the present invention") or metal ion complex (also referred to herein as a "complex of the present invention"), as described below. [0061] In one aspect, the potassium ion channel modulator is a compound according to Formula (I):
Figure imgf000015_0001
In Formula (I), A and B are independently substituted or unsubstituted 5- or 6- membered heterocycloalkyl, or substituted or unsubstituted 5- or 6- membered heteroaryl. The symbol — C= — N— — C=
W1 is I or I . W2 is -CH= -NH-, -N= or -O-. The symbol Z1 is I , Θ — N— — N— I , or II . Z2 is -CH=, -NH-, -N=, or -O-. The symbol X is a bond, -CH2-, or
-NR4-. Y is a bond, -CH=N-NH-, -NH-CH2-, or -NR5-. In some embodiments, X is a bond.
[0062] The symbols s and t are independently integers from 1 to 4. One of skill in the art will immediately recognize that where A is a 5- membered heterocycloalkyl or 5- membered heteroaryl, then s is an integer from 1 to 3; and where A is a 6- membered heterocycloalkyl or 6- membered heteroaryl, then s is an integer from 1 to 4. Likewise, where B is a 5- membered heterocycloalkyl or 5- membered heteroaryl, then t is an integer from 1 to 3 and where B is a 6- membered heterocycloalkyl or 6- membered heteroaryl, then t is an integer from 1 to 4. [0063] The symbol k is an integer from 1 to 2.
[0064] R1 , R2, and R3 are independently H, -OH, -NH2, -NO2, -SO2NH2, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or -NR7R8. [0065] R7 and R8 are independently H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 5- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. R7 and R8 are optionally joined together with the nitrogen to which they are attached to form a substituted or unsubstituted 5- to 7- membered heterocycloalkyl, or substituted or unsubstituted heteroaryl.
[0066] R4 and R5 are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
[0067] Where a plurality of R1, R2, and/or R3 groups are present, each R1, R2, and/or R3 group is optionally different. For example, where s is greater than one, then each R1 is optionally different; where k is greater than one, then each R2 is optionally different; and where t is greater than one, then each R is optionally different. [0068] R1, R2, and R3 may optionally form part of a fused ring system. For example, two R1 groups are optionally joined together with the atoms to which they are attached to form a substituted or unsubstituted 5- to 7- membered ring; two R2 groups are optionally joined together with the atoms to which they are attached to form a substituted or unsubstituted 5- to 7- membered ring; and two R groups are optionally joined together with the atoms to which they are attached to form a substituted or unsubstituted 5- to 7- membered ring. [0069] In some embodiments, A is substituted or unsubstituted heteroaryl. A may also be substituted or unsubstituted pyridinyl. [0070] In other embodiments, A is
Figure imgf000016_0001
In Formula (III), R1 and s are as defined above in the description of Formula (I). In some embodiments, R1 is selected from H, halogen, -NH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 5- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. [0071] A may also be
Figure imgf000017_0001
R1 is as described above in the discussion of Formula (I) of Formula (III). Alternatively, R1 is halogen, or substituted or unsubstituted alkyl. In a related embodiment, R1 is CI or unsubstituted alkyl
(e.g. methyl, ethyl and the like). Thus, A may
Figure imgf000017_0002
[0072] In other embodiments, B is substituted or unsubstituted heteroaryl. B may also be substituted or unsubstituted pyridinyl. Alternatively, B is
Figure imgf000017_0003
In Formula (II), R and t are as defined above in the description of Formula (I). In some embodiments of Formula (II), R3 is H, -NH2, -NO , halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In another
N- embodiment, R3 is CI or -NR7R8. In a related embodiment, R3 is -NH2, -N(CH3)2,
Figure imgf000017_0004
[0073] In other embodiments, B is
Figure imgf000017_0005
or R is as defined above in the description of Formula (I) or Formula (II). In other embodiments, R is substituted or
unsubstituted alkyl (e.g. methyl, ethyl, and the like). Thus, B may be
Figure imgf000017_0006
[0074] R1, R2, and R3 may independently be H, -NH2, -NO2, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or -NR7R8.
[0075] Alternatively, R1 may be H, substituted or unsubstituted (Ci-Cio) alkyl, substituted or unsubstituted 2- to 10- membered heteroalkyl, or substituted or unsubstituted aryl. R1 may also be H, methyl, -NH2, or unsubstituted phenyl.
[0076] R2 may be H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, or substituted or unsubstituted aryl. R2 may also be H, CI, methyl, -OCH3, or unsubstituted pyridinyl. In some embodiments, R2 is H or -OCH3.
[0077] R3 may be H, -NH2, -NO2, halogen, substituted or unsubstituted (Ci-Cio) alkyl, substituted or unsubstituted 2- to 10- membered heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. R may also be H, -NH , -NO , CI, Br, F, methyl, phenyl, fluorophenyl, -CF3, -OCH3, dimethylamino, unsubstituted piperidine, p- methyl morpholino, unsubstituted pyrrolidinonyl, unsubstituted 2-thiophenyl, unsubstituted
3-thiophenyl, unsubstituted furanyl, or n-methyl piperizinyl.
[0078] Alternatively, R3 is CI or -NR7R8, where R7 and R8 are as defined above.
Figure imgf000018_0001
[0079] R ■J> m-ay also be selected , f_rom_ R_J3 i,s C„I, -N ._H. 2, -N «(,C„H. 3). 2, N , . 0„r
[0080] In some embodiments, X is a bond. In a related embodiment k is 2. In a further related embodiment, R2 is H or -OCH3.
[0081] In other embodiments, Y is NH. In a related embodiment, t is 1. In a further related embodiment, B is
Figure imgf000018_0002
R is as defined above in the description of Formula (II). In another related embodiment, B
Figure imgf000018_0003
[0082] The symbol Y may also represent a bond. In a related embodiment, k is 1. In another related embodiment, R is H.
[0083] X may be NH. In some related embodiments, A is
Figure imgf000019_0001
R1 and s are as defined above in the description of Formula (III). In another related
embodiment, A is
Figure imgf000019_0002
[0084] In some embodiments, each substituted moiety described above for the compounds of the present invention is substituted with at least one substituent group. The term "substituent group," as used herein, is defined in detail above in the "Abbreviations and Definitions" section. More specifically, in some embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl described above are substituted with at least one substituent group. Each substituent group is optionally different. In other embodiments, at least one or all of these groups are substituted with at least one size-limited substituent group. Alternatively, at least one or all of these groups are substituted with at least one lower substituent group. Size-limited substituent groups and lower substituent groups are both defined in detail above in the "Abbreviations and Definitions" section. [0085] In other embodiments, each substituted or unsubstituted alkyl is a substituted or unsubstituted Cι-C2n alkyl, and each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2- to 20- membered heteroalkyl.
[0086] Alternatively, each substituted or unsubstituted alkyl is a substituted or unsubstituted Cι-C8 alkyl, and each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2- to 8- membered heteroalkyl.
[0087] In another embodiment, the present invention provides a metal complex modulator, comprising a polyvalent metal ion (e.g. iron, zinc, copper, cobalt, manganese, and nickel) and a polydentate component of a metal ion chelator. The polydentate component is a compound of the present invention (e.g. a compound of Formulae (I), (II), or (III)). The metal complexes of the present invention are potassium ion channel modulators. [0088] In some embodiments, the metal complex modulator has the structure
Figure imgf000020_0001
[0089] In Formula (IV), M is a polyvalent metal ion (e.g. iron, zinc, copper, cobalt, manganese, and nickel). W2 and Z2 are -N=. W1, Z1, R1, R2, R3, X, Y, s, k, t, A, and B are as defined above in the description of the compound of Formula (I).
[0090] Also within the scope of the present invention are compounds of the invention that function as poly- or multi-valent species, including, for example, species such as dimers, trimers, tetramers and higher homologs of the compounds of the invention or reactive analogues thereof. The poly- and multi-valent species can be assembled from a single species or more than one species of the invention. For example, a dimeric construct can be "homo-dimeric" or "heterodimeric." Moreover, poly- and multi-valent constructs in which a compound of the invention or reactive analogues thereof are attached to an oligomeric or polymeric framework (e.g., polylysine, dextran, hydroxyethyl starch and the like) are within the scope of the present invention. The framework is preferably polyfunctional (i.e. having an array of reactive sites for attaching compounds of the invention). Moreover, the framework can be derivatized with a single species of the invention or more than one species of the invention.
Preparation of Potassium Ion Channel Modulators
[0091] The following exemplary schemes illustrate methods of preparing the modulators of the present invention. These methods are not limited to producing the compounds shown, but can be used to prepare a variety of modulators such as the compounds and complexes described above. The modulators of the invention can also be produced by methods not explicitly illustrated in the schemes but are well within the skill of one in the art. The modulators can be prepared using readily available starting materials or known intermediates.
[0092] In the following schemes, the symbol Y is independently selected from CH2, N, S, and O. The symbol D is independently selected from H, -OH, -NH2, -NO2, -SO2NH2, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. The symbol p is an integer independently selected from 1-5. The symbol q is an integer independently selected from 0-5.
[0093] The substituents of the pyrimidinyl compounds of the invention can be produced through the methods outlined in Schemes 1-8.
[0094] In one embodiment, the substituents of the invention comprise amino-substituted heteroaryl moieties as shown in Schemes 1-6.
Scheme 1
Figure imgf000021_0001
80 °C
[0095] In Scheme 1, compound 1 is reacted with benzylamine, followed by debenzylation in concentrated sulfuric acid to produce 2.
[0096] An alternative route to producing compound 2 is shown in Scheme 2.
Scheme 2
Figure imgf000021_0002
[0097] In Scheme 2, a compound 3 is reduced to form compound 2.
[0098] Substituents can be added to the amino-substituted heteroaryl moieties as described in Schemes 3-6. Scheme 3
Figure imgf000022_0001
[0099] In Scheme 3, compound 4 is iodinated to produce a halosubsfituted 2-amino-aza- heterocycle 5. This compound is reacted with a boronic acid 6 in the presence of tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3), and PPh3 in toluene, ethanol, and water to produce 2.
[0100] In another example, amino substituents can be added to the heteroaryl moieties in the following manner.
Scheme 4
Figure imgf000022_0002
5 Trans-1 ,2-cyclohexanediamine dioxane g
[0101] In Scheme 4, an iodo-substituted 2-amino-aza-heterocycle 5 is reacted with an amine 7 or amide using copper catalyzed coupling chemistry to generate a 2-amino-aza- heterocycle 8.
Scheme 5
Figure imgf000022_0003
[0102] In Scheme 5, a bromo-substituted 2-nitro-aza-heterocycle 9 is reacted with an amine 7 or amide using palladium-catalyzed coupling chemistry to generate an aminosubstituted 2-nitro-aza-heterocycle 10. The nitro adduct is reduced to an amino adduct 8 by a palladium catalyzed hydrogenation. Scheme 6
Figure imgf000023_0001
[0103] In Scheme 6, a bromo-substituted 2-nitro-aza-heterocycle 9 is reacted with an amine 7 or amide using copper catalyzed coupling chemistry to generate an aminosubstituted 2-nitro-aza-heterocycle 10. The nitro adduct is reduced to an amino adduct 8 by a palladium catalyzed hydrogenation.
[0104] In one embodiment, the substituents of the invention comprise halo-substituted heteroaryl moieties as shown in Scheme 7.
Scheme 7
Figure imgf000023_0002
ll(shown) Q=l- Br- Cl 12 or 2 or 8
[0105] In Scheme 7, compound 11 or 2 or 8 is halogenated by diazotization followed by sodium nitrite in the presence of acid containing halogen at 0°C to produce compound 12.
[0106] In another embodiment, the substituents of the invention comprise stannyl- substituted heteroaryl moieties as shown in Scheme 8.
Scheme 8
Figure imgf000023_0003
13 Z = H, Q 14
[0107] In Scheme 8, compound 13 is stannylated with /.-butyllithium to produce compound 14. [0108] Stannyl-substituted and halo-substituted heteroaryl moieties can be added to a pyrimidine compound of the invention through the methods outlined in Scheme 9.
Scheme 9
Figure imgf000024_0001
14 15 16
[0109] In Scheme 9, addition of compound 14 to a 2,4-dichloropyrimidine 15 in the presence of a palladium catalyst in toluene produces compound 16.
[0110] An alternative way of producing compound 16 is illustrated in Scheme 10.
Scheme 10
Figure imgf000024_0002
12 (shown) 17 16 or 14
[0111] In Scheme 10, compound 12 or 14 is reacted with 2-chloropyrimidine 17 in the presence of w-butyllithium to produce 16.
[0112] Amino-substituted heteroaryl moieties can be added to a pyrimidine compound of the invention through the methods outlined in Scheme 11.
Scheme 11
Figure imgf000024_0003
15 18
[0113] In Scheme 11, compound 2 or 8 is mixed with sodium hydride to facilitate the nucleophilic addition of 2 or 8 to compound 15 to form compound 18. [0114] Bis-substituted pyrimidines are produced from the method of Scheme 12.
Scheme 12
Figure imgf000025_0001
[0115] In Scheme 12, compound 2 or 8 is mixed with sodium hydride to facilitate the nucleophihc addition of 2 or 8 to compound 16. The final product is a bis-substituted pyrimidine 19.
[0116] An alternative method of producing bis-substituted pyrimidine compounds of the invention is illustrated by Scheme 13.
Scheme 13
Figure imgf000025_0002
18 2. HCl , MeOH 20
[0117] In Scheme 13, compound 14 is added to compound 18 in the presence of a palladium catalyst in toluene to produce the hydrochloride salt of a bis-substituted pyrimidine 20.
[0118] A method of making substituted pyrimidines with a fused aromatic ring is described in Scheme 14.
Scheme 14
Figure imgf000025_0003
[0119] In Scheme 14, compound 21 is reacted with compound 22 in the presence of triethylamine in THF to provide compound 23.
[0120] The pyrimidine ring can be formed by a method outlined in Scheme 15.
Scheme 15
Figure imgf000026_0001
23 24
[0121] In Scheme 15, addition of a base causes the intramolecular cyclization of compound 23 to form compound 24.
[0122] The OH at the 4-position of the pyrimidine ring can be converted into a chlorine by the procedure outlined in Scheme 16.
Scheme 16
Figure imgf000026_0002
24 25
[0123] In Scheme 16, compound 24 is reacted with phosphorus oxychloride in order to produce compound 25.
[0124] A new substituent can be added to the 4-position of the pyrimidine ring as shown in Scheme 17. Scheme 17
Figure imgf000027_0001
25 26
[0125] In Scheme 17, compound 2 or 8 is mixed with sodium hydride to facilitate the nucleophihc addition of 2 or 8 to compound 25. The product is a bis-substituted pyrimidine 26.
[0126] An alternative method of making substituted pyrimidines with a fused aromatic ring is described in Scheme 18.
Scheme 18
Figure imgf000027_0002
27 28 29
[0127] Compound 27 is reacted with stannyl derivative 14 in order to produce compound 28. Compound 28 is then reacted with compound 2 or 8. The product is a bis-substituted pyrimidine 29.
[0128] The compounds of the invention also include metal complexes. These metal complexes comprise a polyvalent metal ion and a pyrimidinyl compound of the invention. In an exemplary embodiment, the polyvalent metal ion can be a transition metal. In another exemplary embodiment, the polyvalent metal ion is a member selected from iron, zinc, copper, cobalt, manganese, and nickel.
[0129] A method of creating metal-pyrimidinyl complexes of the invention is outlined in Scheme 19. Scheme 19
1. M(ll) compound.ether 2 tπethyl amine
Figure imgf000028_0001
Figure imgf000028_0002
nHCI
Figure imgf000028_0003
30
[0130] In Scheme 19, compound 19 or 20 or 26 or 29, or combinations thereof, are first mixed with FeClO4 in ether. To this mixture is added triethylamine which then forms metal complex 30.
III. Assays for Modulators of Potassium Ion Channels
[0131] SK monomers as well as SK alleles and polymorphic variants are subunits of potassium ion channels. The activity of a potassium ion channel comprising SK subunits can be assessed using a variety of in vitro and in vivo assays, e.g., measuring current, measuring membrane potential, measuring ion flow, e.g. , potassium or rubidium, measuring potassium concentration, measuring second messengers and transcription levels, using potassium-dependent yeast growth assays, and using e.g., voltage-sensitive dyes, radioactive tracers, and patchClamp electrophysiology.
[0132] Furthermore, such assays can be used to test for inhibitors and activators of channels comprising SK. The SK family of channels is implicated in a number of disorders that are targets for a therapeutic or prophylactic regimen, which functions by blockade or inhibition of one or more members of the SK channel family. The modulators and methods of the invention are useful to treat central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety, traumatic brain injury, dysmenorrhea, narcolepsy and motor neuron diseases). The modulators of the invention are also useful in treating disease states such as gastroesophogeal reflux disorder and gastrointestinal hypomotility disorders, irritable bowel syndrome, secretory diarrhea, asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, ischemia, cerebral ischemia, ischemic heart disease, angina pectoris, coronary heart disease, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, arrhythmia, hypertension, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.
[0133] Modulators of the potassium ion channels are tested using biologically active SK, either recombinant or naturally occurring, or by using native cells, like cells from the nervous system expressing an SK channel. SK channels can be isolated, co-expressed or expressed in a cell, or expressed in a membrane derived from a cell. In such assays, SK is expressed alone to form a homomeric potassium ion channel or is co-expressed with a second subunit (e.g., another SK family member) so as to form a heteromeric potassium ion channel. Modulation is tested using one of the in vitro or in vivo assays described above. Samples or assays that are treated with a potential potassium ion channel inhibitor or activator are compared to control samples without the test modulator, to examine the extent of modulation. Control samples (untreated with activators or inhibitors) are assigned a relative potassium ion channel activity value of 100. Inhibition of channels comprising SK is achieved when the potassium ion channel activity value relative to the control is less than 70%, preferably less than 40% and still more preferably, less than 30%. Modulators that decrease the flow of ions will cause a detectable decrease in the ion current density by decreasing the probability of a channel comprising SK being open, by decreasing conductance through the channel, and decreasing the number or expression of channels.
[0134] Changes in ion flow may be assessed by determining changes in polarization (i.e., electrical potential) of the cell or membrane expressing the potassium ion channel. A preferred means to determine changes in cellular polarization is by measuring changes in current or voltage with the voltageClamp and patchClamp techniques, using the "cell- attached" mode, the "inside-out" mode, the "outside-out" mode, the "perforated cell" mode, the "one or two electrode" mode, or the "whole cell" mode (see, e.g., Ackerman et al, New Engl J. Med. 336: 1575-1595 (1997)). Whole cell currents are conveniently determined using the standard methodology (see, e.g., Hamil et al, Pflugers. Archiv. 391: 85 (1981)). Other known assays include: radiolabeled rubidium flux assays and fluorescence assays using voltage-sensitive dyes (see, e.g., Vestergarrd-Bogind et al, J. Membrane Biol. 88: 67- 75 (1988); Daniel et al, J. Pharmacol Meth. 25: 185-193 (1991); Holevinsky et al, J. Membrane Biology 137: 59-70 (1994)). Assays for modulators capable of inhibiting or increasing potassium flow through the channel proteins can be performed by application of the modulators to a bath solution in contact with and comprising cells having a channel of the present invention (see, e.g., Blatz et al, Nature 323: 718-720 (1986); Park, J. Physiol. 481: 555-570 (1994)). Generally, the modulators to be tested are present in the range from about 1 pM to about 100 mM, preferably from about 1 pM to about 1 μM.
[0135] The effects of the test modulators upon the function of the channels can be measured by changes in the electrical currents or ionic flow or by the consequences of changes in currents and flow. Changes in electrical current or ionic flow are measured by either increases or decreases in flow of ions such as potassium or rubidium ions. The cations can be measured in a variety of standard ways. They can be measured directly by concentration changes of the ions or indirectly by membrane potential or by radio-labeling of the ions. Consequences of the test modulator on ion flow can be quite varied. Accordingly, any suitable physiological change can be used to assess the influence of a test modulator on the channels of this invention. The effects of a test modulator can be measured by a toxin-binding assay. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as transmitter release (e.g., dopamine), hormone release (e.g., insulin), transcriptional changes to both known and uncharacterized genetic markers (e.g., northern blots), cell volume changes (e.g., in red blood cells), immunoresponses (e.g., T cell activation), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as calcium, or cyclic nucleotides.
IV. Pharmaceutical Compositions For Use as Potassium Ion Channel Modulators
[0136] In another aspect, the present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a modulator of the present invention (e.g. a compound of the present invention or a complex of the present invention). Formulation of the Modulators
[0137] The modulators of the present invention can be prepared and administered in a wide variety of oral, parenteral and topical dosage forms. Thus, the modulators of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the modulators described herein can be administered by inhalation, for example, intranasally. Additionally, the modulators of the present invention can be administered transdermally. Accordingly, the present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and either a modulator, or a pharmaceutically acceptable salt of a modulator.
[0138] For preparing pharmaceutical compositions from the modulators of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
[0139] In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
[0140] The powders and tablets preferably contain from 5% or 10% to 70% of the active modulator. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active modulator with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration. [0141] For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify. [0142] Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution. [0143] Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
[0144] Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
[0145] The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
[0146] The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 10000 mg, more typically 1.0 mg to 1000 mg, most typically 10 mg to 500 mg, according to the particular application and the potency of the active component.
The composition can, if desired, also contain other compatible therapeutic agents.
V. Methods for Decreasing Ion Flow in Potassium Ion Channels
[0147] In yet another aspect, the present invention provides a method for decreasing ion flow through potassium ion channels in a cell, comprising contacting the cell with a potassium ion channel modulating amount of a modulator of the present invention. [0148] In an exemplary embodiment, the potassium ion channels comprise at least one SK subunit.
[0149] The methods provided in this aspect of the invention are useful in the therapy of conditions mediated through potassium ion flow, as well as for the diagnosis of conditions that can be treated by decreasing ion flow through potassium ion channels. Additionally the methods are useful for determining if a patient will be responsive to therapeutic agents which act by modulating potassium ion channels. In particular, a patient's cell sample can be obtained and contacted with a potassium ion channel modulator described above and the ion flow can be measured relative to a cell's ion flow in the absence of the modulator. A decrease in ion flow will typically indicate that the patient will be responsive to a therapeutic regiment of the modulator.
VI. Methods for Treating Conditions Mediated by Potassium Ion Channels
[0150] In still another aspect, the present invention provides a method for treating a disease through the modulation of potassium ion flow through potassium ion channels. The modulation may be activation or inhibition of the potassium ion flow. Thus, the modulators of the present invention may be inhibitors of potassium ion flow through potassium ion channels (i.e. decrease the flow relative to the absence of the modulator) or activators of potassium ion flow through potassium ion channels (i.e. increase the flow relative to the absence of the modulator).
[0151] The modulators are useful in the treatment of central or peripheral nervous system disorders (e.g. , migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety, traumatic brain injury, dysmenorrhea, narcolepsy and motor neuron diseases), and as neuroprotective agents (e.g., to prevent stroke and the like). The modulators of the invention are also useful in treating disease states such as gastroesophogeal reflux disorder and gastrointestinal hypomotility disorders, irritable bowel syndrome, secretory diarrhea, asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, ischemia, cerebral ischemia, ischemic heart disease, angina pectoris, coronary heart disease, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, arrhythmia, hypertension, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression. This method involves administering, to a patient, an effective amount (e.g. a therapeutically effective amount) of a modulator of the present invention (a compound or complex of the present invention).
[0152] Thus, the present invention provides a method of decreasing ion flow through potassium ion channels in a cell. The method includes contacting the cell with a potassium ion channel-modulating amount of a modulator of the present invention. In some embodiments, the potassium ion channel includes at least one SK subunit. The cell may be isolated or form part of a organ or organism.
[0153] The modulators provided herein find therapeutic utility via modulation of potassium ion channels in the treatment of diseases or conditions. The potassium ion channels that are typically modulated are described herein. As noted above, these channels may include homomultimers and heteromultimers.
[0154] In therapeutic use for the treatment of neurological conditions, the modulators utilized in the pharmaceutical method of the invention are administered at the initial dosage of about 0.001 mg/kg to about 1000 mg/kg daily. A daily dose range of about 0.1 mg kg to about 100 mg/kg is more typical. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the modulator being employed. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the modulator. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day.
[0155] The materials and methods of the present invention are further illustrated by the examples which follow. These examples are offered to illustrate, but not to limit, the claimed invention.
EXAMPLES
General
[0156] In the examples below, unless otherwise stated, temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, "rt," or "RT," (typically a range of from about 18-25 °C); evaporation of solvent was carried out using a rotary evaporator under reduced pressure (typically, 4.5-30 mm Hg) with a bath temperature of up to 60 °C; the course of reactions was typically followed by thin layer chromatography (TLC) and reaction times are provided for illustration only; melting points are uncorrected; products exhibited satisfactory ' H-NMR and/or microanalytical data; yields are provided for illustration only; and the following conventional abbreviations are also used: mp (melting point), L (liter(s)), mL (milliliters), mmol (millimoles), g (grams), mg (milligrams), min (minutes), and h (hours). [0157] Unless otherwise specified, all solvents (HPLC grade) and reagents were purchased from suppliers and used without further purification. Reactions were conducted under a blanket of argon unless otherwise stated. Analytical TLC was performed on Whatman Inc. 60 silica gel plates (0.25 mm thickness). Compounds were visualized under UV lamp (254 nM) or by developing with KMnO /KOH, ninhydrin or Hanessian's solution. Flash chromatography was done using silica gel from Selectro Scientific (particle size 32- 63). Η NMR, 19F NMR and 13C NMR spectra were recorded on a Varian 300 machine at 300 MHz, 282 MHz and 75.7 MHz, respectively. Melting points were recorded on a Electrothermal IA9100 apparatus and were uncorrected.
EXAMPLE 1
Preparation of 2 from 1 1.1 Nucleophihc Replacement
[0158] A mixture of 14.7 mmol of 1 and 75 mmol of benzylamine was heated at 220°C for 6 h in a sealed tube. The reaction mixture was concentrated in vacuo and the residue was purified by column chromatography on silica gel to give 7.0 mmol of N-benzyl pyridine-2-amine.
[0159] A solution of 6.9 mmol of N-benzyl pyridin-2-amine in 15 mL of cone. H SO4 was stirred at 80 °C for 1 h. The reaction mixture was poured into crushed ice and neutralized with 28%o ΝH4OH. The mixture was extracted with AcOEt and the organic phase was washed with brine, dried over MgSO4, and concentrated in vacuo. The residue was purified by column chromatography on silica gel to give 5.0 mmol of 2.
1.2 Results
[0160] Analytical data for exemplary compounds of structure 2 are provided below.
1.2. a 5-Hexylpyridin-2-ylamine [0161] Η NMR (300 MHz, CDC13) δ 7.88 (d, J = 2.2 Hz, 1H), 7.26 (dd, J, = 8.4 Hz, J2 = 2.2 Hz, 1H), 6.45 (d, J = 8.4 Hz, 1H), 4.27 (br s, 2H), 2.45 (d, J = 6.6 Hz, 1H), 1.48-1.56 (m, 2H),1.27-1.35 (m, 6H), 0.88 (t, J = 6.6 Hz, 3H); MS m/z: 178 (M+l).
1.2.b 5-tert-Butylpyridin-2-ylamine [0162] Η NMR (300 MHz, CDC13) δ 8.08 (d, J - 2.6 Hz, 1H), 7.47 (dd, J, = 8.6 Hz, J2 = 2.6 Hz, 1H), 6.47 (dd, J, = 8.6 Hz, J2 = 0.7 Hz, 1H), 1.28 (s, 9H); MS m/z: 151 (M+l). 1.2.c 5-[2-(Benzyloxy)ethyllpyridin-2-ylamine [0163] 1H NMR (300 MHz, CDC13) δ 7.94 (d, J = 1.8 Hz, IH), 7.25-7.37 (m, 6H), 6.45 (dd, J, = 8.4 Hz, = 0.7 Hz, IH), 4.51 (s, 2H), 4.31 (br s, 2H), 3.62 (t, J = 6.9 Hz, 2H), 2.78 (t, J = 6.9 Hz, 2H); MS m/z: 228 (M+l).
1.2.d l-(6-Aminopyridin-3-yl)-4-methylpiperazin-2-one [0164] 1H NMR (300 MHz, DMSO-d6) δ 7.80 (d, J = 2.4 Hz, IH), 7.28 (dd, J, = 8.7 Hz, J2 = 2.7 Hz, IH), 6.43 (d, J = 8.8 Hz, IH), 5.97 (br s, 2H), 3.53 (t, J = 5.4 Hz, 2H), 3.06 (s, 2H), 2.68 (t, J = 5.4 Hz, 2H), 2.26 (s, 3H); MS m/z: 279 (M + 1).
EXAMPLE 2
Preparation of 2 from 3 2.1 Catalytic Reduction [0165] A solution or a suspension of 15 mmol of 3 and 0.5 g of Pd/C (10%) in 150 mL of methanol was stirred overnight under H2 (1 atm). After filtering through celite, the solution was concentrated under a reduced pressure to give 15 mmol of 2.
EXAMPLE 3
Preparation of! 3.1 Iodination of 4
[0166] A mixture of 240 mmol of 4, 58 mmol of HIO , and 240 mmol of I2 in 60 mL of water, 4 mL of concentrated H2SO4, and 200 mL of acetic acid was stirred at 80 °C for 4 h. Excess I was neutralized by the addition of 200 mL of saturated Na2S2O solution. The resulting aqueous solution was extracted with EtOAc. The organic phase was washed with saturated NaCl, dried over MgSO4, and concentrated under a reduced pressure. The residue was purified by column chromatography on silica gel to give 136 mmol of 5.
3.2 Suzuki Cross Coupling
[0167] A mixture of 15 mmol of 5, 15 mmol of 6, 0.35 mmol of Pd2(dba) , and 2.4 mmol of PPh3 in 40 mL of toluene, 20 mL of ethanol, and 20 mL of water was refluxed overnight under N2. The reaction mixture was diluted with 300 mL of ethyl acetate and the organic solution was washed with saturated NaCl, dried over MgSO4, and concentrated under a reduced pressure. The residue was purified by column chromatography on silica gel to give 13.1 mmol of 2.
3.3 Results [0168] Analytical data for exemplary compounds of structure 2 are provided below.
3.3. a 5-(2-Methoxy-phenyl)-pyridin-2-ylamine [0169] 1H NMR (300 MHz, DMSO-- ) δ 7.99 (d, J = 2.0 Hz, IH), 7.48 (dd, J, = 8.6 Hz, = 2.3 Hz, IH), 7.26 (d, J = 7.5 Hz, IH), 7.21 (d, J = 6.1 Hz, IH), 7.03 (d, J - 8.0 Hz, IH), 6.96 (t, J = 7.3 Hz, IH), 6.44 (d, J = 8.5 Hz, IH), 5.94 (s, 2H), 3.73 (s, 3H); MS m/z: 201 (M + 1). 3.3.b (5-Methyl-furan-2-yl)-pyridin-2-ylamine [0170] 1H NMR (300 MHz, DMSO-d6) δ 8.17 (d, J = 2.0 Hz, IH), 7.63-7.52 (m, 2H), 6.48 (d, J = 3.2 Hz, IH), 6.43 (d, J = 8.7 Hz, IH), 6.08 (s, 2H), 2.27 (s, 3H); MS m/z: 175 (M + 1).
3.3.c [3, 3 '] Bipyridinyl-6-ylamine
[0171] lH NMR (300 MHz, DMSO-- ) δ 8.78 (d, J = 2.1 Hz, IH), 8.44 (dd, J, = 4.9 Hz, t = 1.6 Hz, IH), 8.27 (d, J = 2.2 Hz, IH), 7.94 (dt, J, = 8.0 Hz, J2 = 1.9 Hz, IH), 7.73 (dd, J, = 8.7 Hz, h = 2.6 Hz, IH), 7.38 (dd, J, = 8.7 Hz, J2 = 2.6 Hz, IH), 6.52 (d, J = 8.7 Hz, IH), 6.17 (s, 2H); MS m/z: 172 (M + 1).
3.3.d 5-(4-Fluoro-phenyl)-4-methyl-pyridin-2-ylamine [0172] 1H NMR (300 MHz, DMSO- 6) δ 7.68 (s, IH), 7.30 (dd, J, = 8.5 Hz, J2 = 5.7 Hz, 2H), 7.19 (t, J = 8.9 Hz, 2H), 6.33 (s, IH), 5.87 (s, 2H), 2.07 (s, 3H); MS m/z: 203 (M + 1).
3.3.e 5-(3-Fluoro-phenyl)-pyridin-2-ylamine [0173] 1H NMR (300 MHz, DMSO- 6) δ 8.27 (d, J = 2.3 Hz, IH), 7.71 (d, J = 8.6 Hz, IH), 7.42-7.38 (m, 3H), 7.08-7.01 (m, IH), 6.49 (d, J = 8.6 Hz, IH), 6.15 (s, 2H); MS m/z: 189 (M + 1).
3.3 f 5-Thiophen-2-yl-pyridin-2-ylamine [0174] 1H NMR (300 MHz, DMSO-- 6) δ 8.19 (d, J = 2.3 Hz, IH), 7.61 (d, J = 8.5 Hz, IH), 7.37 (d, J = 5.1 Hz, IH), 7.25 (d, J = 3.3 Hz, IH), 7.04 (t, J = 4.7 Hz, IH), 6.45 (d, J = 8.7 Hz, IH), 6.14 (s, 2H); MS m/z: 177 (M + 1). EXAMPLE 4
Preparation of from 5 4.1 Ullmann Cross-Coupling
[0175] To a solution of 50.0 mmol of 5 and 60.0 mmol of 7 in 50.0 mL of 1 ,4-dioxane was added 0.500 mmol of copper (I) iodide followed by the addition of 100 mmol of K PO4 and 5 mmol of tr Hs-cyclohexanediamine, then the resulting mixture was stirred at 100°C for 16 h. The reaction mixture was cooled to rt and diluted with 500 mL of H2O. The resulting aqueous solution was extracted with CHC1 . The organic phase was washed with saturated NaCl, dried over MgSO4 and concentrated in vacuo. The crude product was purified by column chromatography to give 43.4 mmol of 8. 4.2 Results
[0176] Analytical data for exemplary compounds of structure 8 are provided below.
4.2. a tert-Butyl 4-(6-aminopyridin-3-yl)-3-oxopiperazine-l -carboxylate [0177] Η NMR (400 MHz, CDC13) δ 7.97-8.00 (m, IH), 7.35-7.40 (m, IH), 6.50-6.54 (m, IH), 4.54 (br s, 2H), 4.24 (s, 2H), 3.65-3.69 (m, 2H), 3.75-3.80 (m, 2H), 1.50 (s, 9H); MS m/z 293 (M+l).
4.2.b 5-(4-Methyl-l ,4-diazepan-l -yl)pyridin-2-ylamine [0178] Η NMR (400 MHz, DMSO-d6) δ 7.46 (d, J= 3.5 Hz, IH), 6.95 (dd, J, = 8.8 Hz, J2 = 3.5 Hz, IH), 6.38 (d, J = 8.8Hz, IH), 5.04 (br s, 2H), 3.26-3.40 (m, 4H), 2.53-2.59 (m, 2H), 2.41-2.47 (m, 2H), 2.24 (s, 3H), 1.78-1.90 (m, 2H); MS m/z: 207 (M+l).
4.2.c 4-(6-Aminopyridin-3-yl)-l -methyl-1 A-diazepan-5-one [0179] 1H NMR (400 MHz, DMSO-d6) δ 7.71 (d, J = 2.9 Hz, IH), 7.18 (dd, J, = 8.8 Hz, J2 = 2.9 Hz, IH), 6.41 (d, J = 8.8 Hz, IH), 5.90 (br s, 2H), 3.64-3.71 (m, 2H), 2.51-2.62 (m, 4H), 2.26 (s, 3H); MS m/z: 221(M+1).
4.2. d tert-Butyl 4-(6-aminopyridin-3-yl)-5-oxo-l,4-diazepane-l -carboxylate [0180] 1H NMR (400 MHz, CDC13) δ 7.90 (d, J = 2.8 Hz, IH), 7.29 (dd, = 8.8 Hz, J2 = 2.8 Hz, IH), 6.50 (d, J = 8.8 Hz, IH), 4.54 (br s, 2H), 3.71-3.75 (m, 6H), 2.80-2.83 (m, 2H), 1.49 (s, 9H); MS m/z: 307 (M+l). EXAMPLE 5
Preparation of 8 5.1 Buchwald Cross-Coupling
[0181] A mixture of 30 mmol of 9, 30 mmol of 7, 0.04 mmol of Pd2(dba)3, 0.08 mmol of rac-2,2'-bis(phenylphosphino)-l,l'-binaphthyl (BINAP), and 42 mmol of Cs2CO3 in 100 mL of dry toluene was stirred at 80 °C for two days under N2. The reaction mixture was diluted with 400 mL of ethyl acetate and the organic solution was washed with saturated NaCl, dried over MgSO4, and concentrated under reduced pressure. The residue was crystallized in ethyl acetate to yield 15.8 mmol of 10.
[0182] A solution or a suspension of 15 mmol of 10 and 0.5 g of Pd/C (10%) in 150 mL of methanol was stirred overnight under H2 (1 atm). After filtering through celite, the solution was concentrated under a reduced pressure to give 15 mmol of 8.
5.2 Results
[0183] Analytical data for exemplary compounds of structure 8 are provided below.
5.2. a 5-(4-Meihyl-piperazin-l-yl)-pyridin-2-ylamine [0184] Η NMR (300 MHz, DMSO-d6) δ 7.56 (d, J = 2.7 Hz, IH), 7.13 (dd, J, = 8.9 Hz, J2 = 2.9 Hz, IH), 6.36 (d, J - 8.8 Hz, IH), 5.36 (s, 2H), 2.89 (t, J = 5.0 Hz, 4H), 2.40 (t, J = 5.0 Hz, 4H), 2.18 (s, 3H); MS m/z: 193 (M + 1).
5.2.b 4-Methyl-3.4, 5.6-tetrahydro-2H-fl .3 '/bipyridinyl-6'-ylamine [0185] Η NMR (300 MHz, DMSO- .6) δ 7.56 (d, J = 2.8 Hz, IH), 7.11 (dd, J, = 8.9 Hz, J2 = 3.0 Hz, IH), 6.35 (d, J = 8.8 Hz, IH), 5.34 (s, 2H), 3.26 (d, J = 12.0 Hz, 2H), 2.45 (dt, J, = 9.3 Hz, J2 = 4.2 Hz, 2H), 1.64 (d, J = 12.5 Hz, 2H), 1.4-1.3 (m, IH), 1.44-1.28 (m, 2H), 0.90 (d, J = 6.5 Hz, 3H); MS m/z: 192 (M + 1).
5.2.C l-(6-Aminopyridin-3-yl)-pyrrolidin-2-one [0186] Η NMR (300 MHz, DMSO- ) δ 8.03 (d, J = 2.6 Hz, IH), 7.63 (dd, J, = 8.9 Hz, J2 = 2.6 Hz, IH), 6.42 (d, J = 8.9 Hz, IH), 5.83 (s, 2H), 3.70 (t, J = 7.0 Hz, 2H), 2.39 (t, J, = 7.8 Hz, 2H), 2.01 (dd, J, = 7.1 Hz, J2 = 7.9 Hz, 2H); MS m/z: 178 (M + 1). 5.2.d l-(6-Aminopyridin-3-yl)piperidin-2-one [0187] Η NMR (400 MHz, DMSO--f6) δ 7.76 (d, J = 2.4 Hz, IH), 7.24 (dd, i = 8.8 Hz, J2 = 2.4 Hz, IH), 6.42 (d, J = 8.8 Hz, IH), 5.90 (br s, 2H), 3.49 (t, J = 6.0 Hz, 2H), 2.34 (t, J = 6.0 Hz, 2H), 1.77-1.85 (m, 4H); MS m/z: 192 (M + 1).
5.2.e l-(6-Aminopyridin-3-yl)piperidin-4-ol [0188] 1H NMR (400 MHz, DMSO-rf6) δ 7.59 (d, J = 2.4 Hz, IH), 7.14 (dd, Ji = 9.2 Hz, J2 = 2.4 Hz, 2H), 6.38 (d, J = 9.2 Hz, IH), 5.34 (br s, 2H), 4.63 (IH, d, J = 4.4 Hz), 3.50-3.57 (m, IH), 3.18-3.23 (m, 2H), 2.59-2.65 (m, 2H), 1.76-1.83 (m, 2H), 1.44-1.54 (m, 2H); MS m/z: 194 (M + l).
5.2.f 5-Piperidin-l-ylpyridin-2-ylamine [0189] Η NMR (400 MHz, CDC13) δ 7.79 (d, J = 2.8 Hz, IH), 7.17 (dd, J, - 8.8 Hz, J2 = 2.8 Hz, IH), 6.47 (dd, Ji = 8.0 Hz, J2 = 0.8 Hz, IH), 4.11 (br s, 2H), 2.98 (d, J = 5.2 Hz, 2H), 2.97 (d, J = 5.2 Hz, 2H), 1.68-1.74 (m, 4H), 1.51-1.57 (m, 2H); MS m/z: 178 (M + 1).
5.2.g 5- (4-Isopropylpiperazin- 1 -yl)pyridin-2-ylam ine [0190] Η NMR (300 MHz, DMSO-d6) δ 7.55-7.60 (m, IH), 7.10-7.17 (m, IH), 6.35-6.42 (m, IH), 5.34 (br s, 2H), 2.85-2.94 (m, 4H), 2.50-2.70 (m, 5H), 0.95-1.02 (m, 6H); MS m/z: 221 (M + l).
5.2.h tert-Butyl 4-(6-aminopyridin-3-yl)piperazine-l -carboxylate [0191] Η NMR (400 MHz, CDC13) δ 7.78 (d, J = 2.8 Hz, IH), 7.17 (dd, J, = 8.8 Hz, J2 = 2.8 Hz, IH), 6.49 (d, J = 8.8 Hz, IH), 4.21 (br s, 2H), 3.57 (t, J = 5.2 Hz, 4H), 2.96 (t, J - 5.2 Hz, 4H), 1.48 (s, 9H); MS m/z: 279 (M + 1).
5.2.i l-(6-Aminopyridin-3-yl)-4-methylpiperazin-2-one [0192] Η NMR (300 MHz, DMSO-d6) δ 7.80 (d, J - 2.4 Hz, IH), 7.28 (dd, J, = 8.7 Hz, J2 = 2.7 Hz, IH), 6.43 (d, J = 8.8 Hz, IH), 5.97 (br s, 2H), 3.53 (t, J - 5.4 Hz, 2H), 3.06 (s, 2H), 2.68 (t, J = 5.4 Hz, 2H),2.26 (s, 3H); MS m/z: 207 (M + 1).
5.2.j 5-f3-(Dimethylamino)pyrrolidin-l-yl/yyridin-2-ylamine [0193] Η NMR (400 MHz, CDC13) δ 7.78 (d, J = 2.8 Hz, IH), 6.83 (dd, Ji = 8.8 Hz, J2 = 2.8 Hz, IH), 6.49 (d, J = 8.8 Hz, IH), 3.96 (br s, 2H), 3.24-3.41 (m, 3H), 3.09 (t, J = 8.0 Hz, IH), 2.82-2.90 (m, IH), 2.35 (s, 6H), 2.14-2.22 (m, IH), 1.86-1.96 (m, IH); MS m/z: 206 (M + 1). 5.2.k N5-l-Azabicvclo[2.2.21 oct-3-ylpyridin-2, 5-yldiamine [0194] 1H NMR (400 MHz, CDC13) δ 7.56 (d, J = 2.8 Hz, IH), 6.86 (dd, J, = 8.4 Hz, J2 = 2.8 Hz, IH), 6.44 (d, J = 8.4 Hz, IH), 4.00 (br s, 2H), 3.34-3.37 (m, IH), 2.80-2.90 (m, 4H), 2.50-2.53 (m, IH), 1.23-1.97 (m, 6H); MS m/z: 218 (M + 1).
5.2.1 5-(2.4,5-Trimethylpiperazin-l-yl)pyridin-2-ylamine [0195] 1H NMR (400 MHz, CDC13) δ 7.91 (d, J = 2.8 Hz, IH), 7.30 (dd, J, = 8.8 Hz, J2 = 2.8 Hz, IH), 6.49 (d, J = 8.8 Hz, IH), 4.29 (br s, 2H), 3.06 (m, IH), 2.86 (dd, J, = 11.2 Hz, h = 3.2 Hz, 2H), 2.66 (m, IH), 2.33 (m, 4H), 2.12 (t, J = 10.8 Hz, IH), 1.07 (d, J = 6.4 Hz, 3H), 0.85 (d, J = 6.4 Hz, 3H); MS m/z: 221 (M + 1).
5.2.m N -Methyl-N -(l-methylpyrrolidin-3-yl)pyridin-2, 5-yldiamine [0196] 1H NMR (400 MHz, CDC13) δ 7.78 (d, J = 2.8 Hz, IH), 7.16 (dd, J! = 8.8 Hz, J2 = 2.8 Hz, IH), 6.47 (d, J = 8.8 Hz, IH), 4.12 (br s, 2H), 3.97-4.04 (m, IH), 2.72 (s, 3H), 2.60-2.70 (m, 2H), 2.50-2.56 (m, 2H), 2.34 (s, 3H), 2.04-2.10 (m, IH), 1.77-1.83 (m, IH); MS m/z: 207 (M + l).
5.2.n 5-(3-Methylpiperazin-l-yl)pyridin-2-ylamine [0197] 1H NMR (400 MHz, CDC13) δ 7.74 (d, J = 2.8 Hz, IH), 7.15 (dd, J, = 8.8 Hz, J2 = 2.8 Hz, IH), 6.48 (d, J = 8.8 Hz, IH), 4.33 (m, IH), 4.21 (br s, 2H), 3.92-3.96 (m, IH), 3.19-3.26 (m, 2H), 3.08-3.11 (m, IH), 2.82 (dd, J, = 11.6 Hz, J2 - 4.0 Hz, IH), 2.61-2.68 (m, IH), 1.48 (s, 9H), 1.32 (d, J = 6.8 Hz, 3H); MS m/z: 293 (M + l).
5.2.0 5-(3,5-Dimethylpiperazin-l-yl)pyridin-2-ylamine [0198] 1H NMR (400 MHz, CDCI3) δ 7.76 (d, J = 2.8 Hz, IH), 7.16 (dd, Ji = 8.8 Hz, J2 = 2.8 Hz, IH), 6.50 (d, J = 8.8 Hz, IH), 4.18-4.24 (m, 2H), 3.08-3.11 (m, 2H), 2.80 (dd, J, = 11.6 Hz, J2 = 4.0 Hz, IH), 1.49 (s, 9H), 1.37 (d, J = 6.8 Hz, 6H); MS m/z: 307 (M+l).
5.2.p N -(2-Methoxyeihyl)-N -methylpyridin-2, 5-yldiamine [0199] MS m/z 182 (M+l).
5.2.q 5-(4-Methoxypiperidin-l-yl)nyridin-2-ylamine [0200] MS m/z: 208 (M+l). EXAMPLE 6
Preparation ofS 6.1 Ullmann Cross-Coupling
[0201] To a solution of 24.6 mmol of 9 and 27.3 mmol of 7 in 50 mL of 1 ,4-dioxane was added 4.92 mmol of copper (I) iodide followed by the addition of 49.2 mmol of K3PO4 and 4.92 mmol of tr ns-cyclohexanediamine, then the resulting mixture was stirred at 100°C for 12 h. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was diluted with CHC13, poured into water, and insoluble material was removed by celite filtration. The filtrate was extracted with CHCI3, dried over MgSO4 and concentrated in vacuo. The crude product was purified by column chromatography to give 7.87 mmol of nitro derivative.
[0202] A solution of 7.66 mmol of nitro derivative and 0.5 g of Pd/C (10%) in 150 mL of methanol was stirred overnight under H2 (1 atm). After filtering through celite, the solution was concentrated under reduced pressure to give 4.75 mmol of 8.
6.2 Results
[0203] Analytical data for exemplary compound of structure 8 are provided below.
6.2. a 4-(6-Aminopyridin-3-yl)-l-benzyl-l,4-diazepan-5-one [0204] Η NMR (400 MHz, DMSO-rfβ) δ 7.70 (d, J = 2.4 Hz, IH), 7.17 (dd, J, = 8.8 Hz, J2 = 2.4 Hz, IH), 7.30-7.36 (m, 5H), 6.40 (d, J = 8.8 Hz, IH), 5.90 (br s, 2H), 3.66-3.72 (m, 2H), 3.59 (br s, 2H), 2.59-2.71 (m, 6H); MS m/z: 327 (M+l).
EXAMPLE 7
Preparation of 12 7.1 Halogenation [0205] To a solution of 30.7 mmol of 11 and 5 mL of bromine in 48 mL of hydrobromic acid (48%) at 0 °C was added 24 mL (25 M) of aqueous NaNO2. The mixture was stirred for 1 h at rt before it was neutralized by 145 mL of 3M NaOH. The aqueous solution was extracted with ethyl acetate, and the organic phase was washed with saturated NaCl, dried over MgSO4, and concentrated under a reduced pressure. The crude product was purified by column chromatography to give 24.6 mmol of 12. 7.2 Results [0206] Analytical data for exemplary compounds of structure 12 are provided below.
7.2. a 2-Bromo-5-chloro-pyridine [0207] Η NMR (300 MHz, DMSO-c.6) δ 8.47 (d, J = 2.8 Hz, IH), 7.89 (dd, Ji = 8.5 Hz, J2 = 2.7 Hz, IH), 7.69 (d, J = 8.5 Hz, IH); MS m/z: 192 (M + 1).
7.2.b 2-Bromo-5-(4-fluoro-phenyl)-pyridine [0208] Η NMR (300 MHz, DMSO- 6) δ 8.68 (d, J = 2.4 Hz, IH), 8.03 (dd, Ji = 8.3 Hz, J2 = 2.6 Hz, IH), 7.80-7.70 (m, 3H), 7.34 (d, J = 6.6 Hz, IH), 7.32 (d, J = 6.8 Hz, IH); MS m/z: 252 (M + l).
EXAMPLE 8
Preparation of 14 8.1 Stannylation
[0209] To a solution of 17.4 mmol of 13 in 60 mL of dry THF at -78 °C under N2 was added 19.2 mmol of w-BuLi (2.5 M in hexane), and the resulting brown solution was stirred for 30 min before 20.9 mmol of Bu3SnCl was added. The reaction mixture was allowed to warm to room temperature overnight. After the reaction was quenched with saturated NH4C1 and the mixture was extracted with ethyl acetate, the combined organic phase was washed with saturated NaCl, dried over MgSO4, and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel to give 10.5 mmol of l4.
8.2 Results
[0210] Analytical data for exemplary compounds of structure 14 are provided below.
8.2. a 4-Methyl-2-tributylstannanyl-pyridine [0211] Η NMR (300 MHz, CDC13) δ 8.57 (d, J = 5.0 Hz, IH), 7.21 (s, IH), 6.93 (d, J = 4.7 Hz, IH), 2.29 (s, 3H), 1.61-1.47 (m, 6H), 1.39-1.29 (m, 6H), 1.16-1.08 (m, 6H), 0.87 (t, J = 7.3 Hz, 9H); MS m/z: 384 (M + 1). 8.2.b 2-Methoxy-6-tributylstannanyl-pyridine [0212] Η NMR (300 MHz, CDC13) δ 7.39 (dd, J, = 8.3 Hz, J2 = 6.9 Hz, IH), 6.98 (d, J = 6.1 Hz, IH), 6.55 (d, J = 8.4 Hz, IH), 3.93 (s, 3H), 1.62-1.53 (m, 6H), 1.38-1.27 (m, 6H), 1.12-1.05 (m, 6H), 0.89 (t, J = 5.9 Hz, 9H); MS m/z: 400 (M + 1).
8.2.c 5-Methyl-2-tributylstannanyl-pyridine [0213] 1H NMR (300 MHz, CDC13) δ 8.56 (s, IH), 7.30-7.24 (m, 2H), 2.25 (s, 3H), 1.58-1.44 (m, 6H), 1.36-1.25 (m, 6H), 1.11-1.04 (m, 6H), 0.86 (t, J = 7.1 Hz, 9H); MS m/z: 384 (M + 1).
8.2.d 4-Pyrrolidin-l-yl-2-tributylstannanyl-pyridine [0214] Η NMR (300 MHz, DMSO-cfc) δ 8.14 (d, J - 4.5 Hz, IH), 6.68-6.64 (m, IH), 6.59 (d, J = 2.4 Hz, IH), 3.41 to 3.39 (m, 4H), 1.97 (bs, 4H), 1.58-1.41 (m, 6H), 1.38-1.22 (m, 6H), 1.20-1.00 (m, 6H), 0.83 (t, J = 7.3 Hz, 9H); MS m/z: 439 (M + 1).
EXAMPLE 9
Preparation of 16 9.1 General Method: Stille Cross-Coupling
[0215] A mixture of 0.3 mmol of 15, 0.36 mmol of 14, and 0.015 mmol of Pd(PPh3)4 in 4 mL of dry toluene was stirred for 2 days at 70 °C under N2. The reaction was quenched with 10 mL of saturated NH4C1. After the mixture was extracted with EtOAc, the organic phase was washed with saturated NaCl, dried over MgSO4, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to give 0.063 mmol of 16.
9.2 Results
[0216] Analytical data for an exemplary compound of structure 16 is provided below.
9.2. a 2-Chloro-4-pyridin-2-yl-pyrimidine [0217] Η NMR (300 MHz, DMSO-</6) δ 8.79 (d, J = 5.0 Hz, IH), 8.73 (d, J = 3.8 Hz, IH), 8.47 (d, J = 8.0 Hz, IH), 8.36 (d, J = 5.2 Hz, IH), 8.03-7.97 (m, IH), 7.58-7.53 (m, lH); MS m/z: 192 (M + l). EXAMPLE 10
Preparation of 16 10.1 General Method: Nucleophihc Addition and Oxidation [0218] To a solution of 127 mmol of 14 in 400 mL of dry THF at -78 °C was added 139 mmol of tt-butyllithium (2.5 M in hexane) and the solution was stirred for 30 min before 139 mmol of 17 in 100 mL of dry THF was added over a period of 10 min. The resulting mixture was allowed to warm to room temperature with stirring overnight. The reaction was quenched with 10 mL of acetic acid. To the acidic mixture was added 139 mmol of DDQ and the resulting mixture was stirred for 2 days at room temperature before it was quenched with saturated NaHCO3. After the mixture was extracted with ethyl acetate, the organic phase was washed with saturated NaCl, dried over MgSO , and concentrated in vacuo to afford 62 mmol of 16.
EXAMPLE 11
Preparation of 8 11.1 General Method
[0219] To a solution of 1.34 mmol of 2 or 8 in 20 mL of anhydrous THF was added 2.68 mmol of NaH (60% in mineral oil) and the solution was stirred for 10 min before the addition of 1.34 mmol of 15. The resulting mixture was stirred at reflux for 1 day under N2 and the reaction was quenched with saturated NH4C1. The reaction mixture was diluted with 100 mL of ethyl acetate and the organic solution was washed with saturated NaCl, dried over MgSO4, and concentrated in vacuo. The crude product was purified by column chromatography on silica gel to afford 0.48 mmol of 18.
11.2 Results
[0220] Analytical data for exemplary compounds of structure 18 are provided below.
11.2. a (2-Chloro-pyrimidin-4-yl)-pyridin-2-yl-amine [0221] Η NMR (300 MHz, DMSO-t 6) δ 10.67 (s, IH), 8.32 (d, J = 6.0 Hz, 2H), 7.83 (d, J = 5.5 Hz, IH), 7.81-7.74 (m, IH), 7.50 (d, J = 8.3 Hz, IH), 7.07-7.02 (m, IH); MS m/z: 207 (M + l). 11.2. b (5-Chloro-pyridin-2-yl)-(2-chloro-pyrimidin-4-yl)-amine [0222] 1H NMR (300 MHz, DMSO--.6) δ 10.83 (s, IH), 8.35 (d, J = 5.8 Hz, 2H), 7.90 (dd, Ji = 2.8 Hz, J2 = 8.9 Hz, IH), 7.71 (d, J = 5.7 Hz, IH), 7.60 (d, J = 9.1 Hz, IH); MS m/z: 241 (M + 1).
EXAMPLE 12
Preparation of 19 12.1 General Method: Nucleophilic Replacement
[0223] To a solution of 0.58 mmol of 2 or 8 in 20 mL of anhydrous THF was added 1.05 mmol of NaH (60% in mineral oil) and the solution was stirred for 10 min before the addition of 0.53 mmol of 16. The resulting mixture was stirred at reflux for 16 h under N2 and then the reaction was quenched with saturated NH4C1. The reaction mixture was diluted with 100 mL of ethyl acetate and the organic solution was washed with saturated NaCl, dried over MgSO4, and concentrated in vacuo. The crude product was purified by column chromatography on silica gel to afford a quantitative yield of 19.
12.2 Results
[0224] Analytical data for exemplary compounds of structure 19 are provided below.
12.2. a (5-Methoxy-2-pyridin-2-yl-pyrimidin-4-yl)-pyridin-2-yl-amine [0225] 1H NMR (300 MHz, DMSO- /6) δ 10.75 (bs, IH), 8.90 (d, J = 5.2 Hz, IH), 8.59-8.48 (m, 3H), 8.40 (t, J = 7.8 Hz, IH), 8.26-8.12 (m, 2H), 7.90 (t, J = 6.4 Hz, IH), 7.44-7.39 (m, IH), 4.12 (s, 3H); MS m/z: 280 (M + 1).
12.2.b (5-Chloro-pyridin-2-yl)-(5-methoxy-2-pyridin-2-yl-pyrimidin-4-yl)- amine - 2HCI
[0226] 1H NMR (300 MHz, DMSO- 6) δ 10.10 (s, IH), 8.86 (d, J = 4.7 Hz, IH), 8.52-
8.32 (m, 4H), 8.26 (d, J = 8.9 Hz, IH), 8.06 (dd, Ji = 8.9 Hz, J2 = 2.5 Hz, IH), 7.92-7.87 (m,
IH), 4.09 (s, 3H); MS m/z: 314 (M + 1).
12.2.C (5-Methoxy-2-pyridin-2-yl-pyrimidin-4-yl)-(5-pyrrolidin-l-yl-pyridin- 2-vD- amine • 2HCI
[0227] Η NMR (300 MHz, DMSO--4) δ 10.85 (bs, IH), 8.89 (d, J = 5.0 Hz, IH), 8.45 (d,
J = 7.8 Hz, IH), 8.35 (s, 2H), 7.97 (d, J = 9.4 Hz, IH), 7.91-7.86 (m, IH), 7.84 (d, J = 3.0 Hz, IH), 7.55 (dd, J! = 9.3 Hz, J2 = 3.0 Hz, IH), 4.11 (s, 3H), 3.37-3.30 (m, 4H), 1.99 (t, J = 6.4 Hz, 4H); MS m/z: 349 (M + l).
12.2. d [5-(3-Fluoro-phenyl)-pyridin-2-yl]-(5-methoxy-2-pyridin-2-yl- pyrimidin-4-yl)- amine • 2HCI
[0228] Η NMR (300 MHz, DMSO- ) δ 10.55 (bs, IH), 8.93-8.89 (m, 2H), 8.56 (d, J =
7.9 Hz, IH), 8.46-8.41 (m, 3H), 8.34 (d, J = 8.7 Hz, IH), 7.96-7.91 (m, IH), 7.71-7.63 (m,
2H), 7.59-7.51 (d, IH), 7.30-7.22 (m, IH), 4.12 (s, 3H); MS m/z: 374 (M + 1).
12.2.e l-[6-(5-Methoxy-2-pyridin-2-yl-pyrimidin-4-ylamino)-pyridin-3-yl/- pyrrolidin-2-one • 2HCI
[0229] 1H NMR (300 MHz, DMSO-_/6) δ 10.27 (bs, IH), 8.86 (d, J = 4.7 Hz, IH), 8.73 (d,
J = 2.7 Hz, IH), 8.45 (d, J = 7.8 Hz, IH), 8.40-8.30 (m, 4H), 7.88-7.83 (m, IH), 4.10 (s,
3H), 3.90 (t, J = 7.0 Hz, 2H), 2.55-2.47 (m, 2H), 2.11 (t, J = 7.5 Hz, 2H); MS m/z: 363 (M +
!)• 12.2f (5-Methoxy-2-pyridin-2-yl-pyrimidin-4-yl)-[5-(4-methyl-piperazin-l- yl)-pyridin-2-ylJ -amine ■ 3HCI
[0230] 1H NMR (300 MHz, DMSO--4) δ 10.67 (bs, IH), 8.88 (d, J = 4.6 Hz, IH), 8.38 (d,
J = 7.8 Hz, IH), 8.31-8.26 (m, 3H), 8.01 (d, J = 9.0 Hz, IH), 7.86-7.78 (m, 2H), 4.10 (s,
3H), 3.94 (d, J = 12.7 Hz, 2H), 3.50 (d, J = 11.7 Hz, 2H), 3.32-3.14 (m, 4H), 2.79 (d, J = 4.5
Hz, 3H); MS m/z: 378 (M + 1).
12.2. g (5-Methoxy-2-pyrιdin-2-yl-pyrimidin-4-yl)-(4-methyl-3.4.5.6- tetrahydro-2H-f 1 ,3'l bipyridinyl-6'-yl)- amine ■ 2HCI
[0231] 1H NMR (300 MHz, DMSO- 6) δ 10.59 (bs, IH), 8.91 (d, J = 4.9 Hz, IH),
8.58-8.44 (m, 3H), 8.43 (s, IH), 8.25-8.19 (m, 2H), 8.00-7.94 (m, IH), 4.11 (s, 3H), 3.71 (d,
J = 11.8 Hz, 2H), 3.16 (bs, 2H), 1.78 (d, J = 12.5 Hz, 2H), 1.70-1.45 (m, 3H), 0.95 (d, J =
6.1 Hz, 3H); MS m/z: 311 (M + 1).
EXAMPLE 13
Preparation of 20 13.1 Negishi Cross-Coupling [0232] A mixture of 0.08 mmol of 18, 0.08 mmol of 14, and 0.015 mmol of Pd(PPh3)4 in 4 mL of dry THF was stirred at reflux for 2 days under N2. The reaction was quenched with 10 mL of saturated NH4C1. After the mixture was extracted with EtOAc, the organic phase was washed with saturated NaCl, dried over MgSO4, and concentrated in vacuo. The residue was purified by column chromatography on silica gel to give 0.03 mmol of 20.
13.2 Results [0233] Analytical data for exemplary compounds of structure 20 are provided below.
13.2. a Pyridin-2-yl-(4-pyridin-2-yl-pyrimidin-2-yl)-amine [0234] Η NMR (300 MHz, DMSO--4) δ 9.91 (s, IH), 8.74 (d, J = 3.5 Hz, IH), 8.69 (d, J = 5.1 Hz, IH), 8.42 (d, J = 7.8 Hz, IH), 8.34 (d, J - 8.3 Hz, IH), 8.30 (d, J = 3.6 Hz, IH),
8.04 (t, J = 7.8 Hz, IH), 7.81 (d, J = 4.8 Hz, 2H), 7.59-7.54 (m, IH), 7.03-6.98 (m, IH); MS m/z: 250 (M + l).
13.2. b (5-Chloro-pyridin-2-yl)-(4-pyridin-2-yl-pyrimidin-2-yl)-amine [0235] 1H NMR (300 MHz, DMSO-- ) δ 10.24 (s, IH), 8.76-8.69 (m, 2H), 8.43-8.32 (m, 2H), 8.03 (dd, J, = 7.8 Hz, J2 = 6.0 Hz, IH), 7.90 (dd, Ji = 8.9 Hz, J2 = 2.5 Hz, IH), 7.86- 7.82 (m, IH), 7.61-7.54 (m, 2H); MS m/z: 284 (M + 1).
13.2.C (5-Phenyl-vyridin-2-yl)-(4-vyridin-2-yl-pyrimidin-2-yl)-amine [0236] 1H NMR (300 MHz, DMSO-rf6) δ 10.12 (s, IH), 8.76-8.71 (m, 2H), 8.64 (d, J =
2.5 Hz, IH), 8.45 (d, J = 8.3 Hz, 2H), 8.14 (dd, J, = 2.4 Hz, J2 = 8.7 Hz, IH), 8.04 (dt, J, = 1.8 Hz, J2 = 7.8 Hz, IH), 7.82 (d, J = 5.0 Hz, IH), 7.71 (d, J = 7.3 Hz, 2H), 7.60-7.55 (m, IH), 7.50-7.44 (m, 2H), 7.37 (d, J = 7.3 Hz, IH); MS m/z: 326 (M + 1).
EXAMPLE 14
Preparation of '23 14.1 General Method [0237] A mixture of 20.0 mmol of the corresponding carboxylic acid of 22, 15 mL of SOCl2, and 5 drops of DMF was stirred at 60°C for 3 h. The reaction mixture was concentrated in vacuo. To a solution of the crude 22 in 50 mL of THF was added 20 mmol of 21 and 60 mmol of Et3N and stirred at room temperature for 2 h. The reaction mixture was concentrated and the residue was diluted with water and AcOEt. The precipitates were collected by filtration and washed with EtOH to give 1.1 mmol of 23. EXAMPLE 15
Preparation of 24 15.1 General Method [0238] To a solution of 6.9 mmol of 23 in 20 mL of THF and 20 mL of t-BuOH was added 15 mmol of tBuOK and stirred at 80°C for 2 h. The reaction mixture was quenched with 3 g of NH4C1 and extracted with AcOEt. The organic phase was washed with brine, dried over MgSO4, and concentrated in vacuo. The residue was washed with AcOEt-n- hexane (1:2) to give 6.1 mmol of 24.
EXAMPLE 16
Preparation of 25 16.1 General Method
[0239] A mixture of 5.5 mmol of 24 in 15 mL of POCl3 was stirred at 120°C for 1 h. The reaction mixture was concentrated in vacuo and diluted with AcOEt and H2O, and quenched with K2CO3. The precipitates were collected by filtration to give 4.7 mmol of 25.
16.2 Results
[0240] Analytical data for exemplary compound of structure 25 is provided below.
16.2. a 4-Chloro-2-pyridin-2-ylquinazoline [0241] ]H NMR (400 MHz, CDC13) δ 8.79 (d, J = 4.9 Hz, IH), 8.50 (d, J = 7.8 Hz, IH), 8.20 (dd, Ji = 7.8 Hz, J2 = 1.0 Hz, IH), 8.11 (dt, J, = 7.8 Hz, J2 = 1.5 Hz, IH), 7.83-7.92 (m, 2H), 7.68-7.71 (m, IH), 7.57-7.61 (m, IH); MS m/z: 243 (M + 1).
EXAMPLE 17
Preparation of 26 17.1 General Method [0242] To a solution of 1.66 mmol of 25 in 15 mL of DMF was added 5 mmol of 60% NaH in oil at room temperature and 1.66 mmol of 2 or 8, and the resulting mixture was stirred at 60°C for 4 h. The reaction mixture was concentrated in vacuo and the residue was diluted with water and AcOEt. The mixture was extracted with AcOEt and the organic phase was extracted with diluted HCl. Aqueous phase was made alkaline with K2CO and extracted with AcOEt, and then organic phase was washed with brine, dried over MgSO4, and concentrated. The residue was purified by column chromatography on silica gel to give 0.94 mmol of ca. 1 :1 tautomeric mixture of 26.
17.2 General Method [0243] Analytical data for exemplary compound of structure 26 is provided below.
17.2. a N 2-dipyridin-2-ylquinazolin-4-amine and N-fC4Z)-2-pyridin-2- ylquinazolin-4(3H)-ylidene/pyridin-2-amine (ca. 1:1 tautomeric mixture)
[0244] Η NMR (400 MHz, DMSO-- ) δ 10.18 (s, 0.5H), 8.72-8.86 (m, 2H), 8.42-8.57
(m, 2.5H), 8.08 (dt, J, = 7.8 Hz, J2 = 2.0 Hz, 0.5H), 7.47-7.98 (m, 6H), 7.32 (d, J = 8.3 Hz,
0.5H), 7.11-7.17 (m, IH); MS m/z: 300 (M + l).
EXAMPLE 18
Preparation of 29 18.1 General Method
[0245] A mixture of 3.0 mmol of 27, 3.0 mmol of 14, and 0.09 mmol of Pd(PPh3)4 in 20 mL of toluene was stirred at 100°C for 20 h. The reaction mixture was diluted with AcOEt and H2O, filtrated through celite, and then extracted with AcOEt. The organic phase was washed with brine, dried over MgSO4 and concentrated in vacuo. The residue was purified by column chromatography on silica gel to give 0.46 mmol of 28.
18.2 Results
[0246] Analytical data for exemplary compound of structure 28 is provided below.
18.2. a 2-Chloro-4-pyridin-2-ylquinazoline [0247] 1H NMR (300 MHz, CDC13) δ 8.95-8.99 (m, IH), 8.83-8.86 (m, IH), 8.27 (dt, J, = 7.9 Hz, J2 = 0.9 Hz, IH), 7.92-8.07 (m, 3H), 7.65-7.71 (m, IH), 7.49-7.54 (m, IH); MS m/z: 243 (M + l).
18.3 General Method
[0248] To a solution of 1.66 mmol of 28 in 15 mL of DMF was added 5 mmol of 60% NaH in oil at room temperature and 1.66 mmol of 2 or 8, and the resulting mixture was stirred at 60°C for 4 h. The reaction mixture was concentrated in vacuo and the residue was diluted with water and AcOEt. The mixture was extracted with AcOEt and the organic phase was extracted with diluted HCl. Aqueous phase was made alkaline with K2CO3 and extracted with AcOEt, and then organic phase was washed with brine, dried over MgSO4, and concentrated. The residue was purified by column chromatography on silica gel to give 0.90 mmol of 29.
18.4 Results [0249] Analytical data for exemplary compound of structure 29 is provided below.
18.4. a N4-Dipyridin-2-ylquinazolin-2-amine [0250] 1H NMR (400 MHz, DMSO--.6) δ 10.03 (s, IH), 8.84 (d, J = 5.4 Hz, IH), 8.64 (d, J = 7.8 Hz, IH), 8.60 (d, J = 8.3 Hz, IH), 8.34 (d, J = 4.9 Hz, IH), 8.21 (d, J = 7.8 Hz, IH), 8.11 (dt, Ji = 7.4 Hz, J2 = 1.5 Hz, IH), 7.82-7.90 (m, 3H), 7.64-7.67 (m, IH), 7.44 (t, J = 7.8 Hz, IH), 7.02-7.06 (m, IH); MS m/z: 300 (M + 1).
EXAMPLE 19
Preparation of the metal complex 30 19.1 Synthesis [0251] 0.1 mL of 1.0 M FeClO4 in ether is added to a solution of 0.2 mmol of 20 in EtOH at 60 °C. A white precipitate forms immediately. To this mixture is added 0.06 mL of triethyl amine and the resulting mixture is stirred for 20 min. After the mixture is cooled to rt, the white precipitate is filtered to yield 30.
EXAMPLE 20 20.1 Assay for Compound Activity Towards hSK Channels [0252] Cells expressing small conductance, calcium activated potassium channels, such as SK-like channels were loaded with 86Rb+ by culture in media containing 86RbCl. Following loading, the culture media was removed and the cells were washed in EBSS to remove residual traces of 86Rb+. Cells were preincubated with the drug (0.01 to 30 μM in EBSS) and then 86Rb+ efflux was stimulated by exposing cells to EBSS solution supplemented with a calcium ionophore, such as ionomycin, in the continued presence of the drug. After a suitable efflux period, the EBSS/ionophore solution was removed from the cells and the 86Rb+ content was determined by Cherenkov counting (Wallac Trilux). Cells were then lysed with a SDS solution and the 86Rb+ content of the lysate was determined. Percent 86Rb+ efflux was calculated according to the following equation:
(86Rb+ content in EBSS/(86Rb+ content in EBSS + 86Rb+ content of the lysate)) X 100
20.2 Results
[0253] Compounds tested in this assay, along with their hSK2 inhibitory activity, are provided in Table 1.
Table 1
Figure imgf000052_0001
Figure imgf000053_0001
Key: + indicates 30 μM>IC50>5.0 μM; ++ indicates 5.0 μM>IC50>1.0 μM; +++ indicates 1.0 μM>IC50>0.1 μM; ++++ indicates 0.1 μM>IC50>0.0 μM.
[0254] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

Claims

WHAT IS CLAIMED IS:
A compound having a structure according to Formula I:
Figure imgf000054_0001
wherein A and B are independently substituted or unsubstituted 5- or 6- membered heterocycloalkyl, or substituted or unsubstituted 5- or 6- membered heteroaryl, — C= — N— W' is 1 or 1 ; W2 is -CH=, -NH-, -N= or -O-; Θ — C= — N— — N— Z' is 1 1 , or II Z2 is -CH=, -NH-, -N=, or -O-; X is a bond, -CH2-, or -NR4-; Y is a bond, -CH=N-NH-, -NH-CH2-, or -NR5-; s and t are independently integers from 1 to 4; k is an integer from 1 to 2; R1 , R2, and R3 are independently H, -OH, -NO2, -SO2NH2, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or -NR7R8, wherein R7 and R8 are independently H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 5- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein R and R are optionally joined together with the nitrogen to which they are attached to form a substituted or unsubstituted 5- to 7- membered heterocycloalkyl, or substituted or unsubstituted heteroaryl; and R4 and R5 are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; wherein if s is greater than one, then each R1 is optionally different; wherein if k is two, then each R2 is optionally different; wherein if t is greater than one, then each R is optionally different; wherein two R1 groups are optionally joined together with the atoms to which they are attached to form a substituted or unsubstituted ring; wherein two R2 groups are optionally joined together with the atoms to which they are attached to form a substituted or unsubstituted ring; and wherein two R3 groups are optionally joined together with the atoms to which they are attached to form a substituted or unsubstituted ring.
2. The compound of claim 1, wherein A is substituted or unsubstituted pyridinyl.
3. The compound of claim 1, wherein B is substituted or unsubstituted pyridinyl. 1 7 ^
4. The compound of claim 1, wherein R , R , and R are independently H, -NH2, -NO2, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
5. The compound of claim 4, wherein R1 is H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted aryl; R2 is H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstihited 5- to 7- membered heterocycloalkyl, or substituted or unsubstituted aryl; R3 is H, -NH2, -NO2, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
6. The compound of claim 5, wherein R1 is H, methyl, -NH2, or unsubstituted phenyl; R is H, CI, methyl, -OCH3, or unsubstituted pyridinyl; and R3 is H, -NH2, -NO2, CI, Br, F, methyl, phenyl, fluorophenyl, -CF3, -OCH3, dimethylamino, unsubstituted piperidine, /?-mefhyl morpholino, unsubstituted pyrrolidinonyl, unsubstituted 2-thiophenyl, unsubstituted 3-thiophenyl, unsubstituted furanyl, or n-methyl piperizinyl.
7. The compound of claim 2, wherein X is a bond, k is 2, and R2 is H or -OCH3.
8. The compound of claim 7, wherein Y is -NH-, t is 1, and B is
Figure imgf000056_0001
wherein R .3 : i,s H, -NH2, -NO2, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
9. The compound of claim 8, wherein R is Cl or -NR7R8, wherein R and R are independently H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 5- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein R7 and R8 are optionally joined together with the nitrogen to which they are attached to form a substituted or unsubstituted 5- to 7- membered heterocycloalkyl, or substituted or unsubstituted heteroaryl.
10. The compound of claim 9, wherein R3 is CI, -NH2, -N(CH3)2,
Figure imgf000057_0001
11. The compound of claim 7, wherein Y is -NH- and B is
Figure imgf000057_0002
12. The compound of claim 3, wherein Y is a bond, k is 1 and R is H
13. The compound of claim 12, wherein X is -NH- and A is
Figure imgf000057_0003
wherein s is an integer froml to 4; and R1 is H, halogen, -NH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 5- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
14. The compound of claim 13, wherein A is
Figure imgf000057_0004
15. A metal complex, comprising a polyvalent metal ion and a polydentate component of a metal ion chelator, wherein said polydentate component is a compound according to claim 1.
16. The complex of claim 15, wherein said polyvalent metal ion is selected from iron, zinc, copper, cobalt, manganese, and nickel.
17. A method of decreasing ion flow through potassium ion channels in a cell, said method comprising contacting said cell with a potassium ion channel-modulating amount of a compound of one of claims 1-14 or a metal complex of one of claims 15 or 16.
18. The method according to claim 17, wherein said potassium ion channel comprises at least one SK subunit.
19. A method of treating a disease through modulation of a potassium ion channel, said method comprising administering to a subject in need of such treatment, an effective amount of a compound of one of claims 1-14 or a metal complex of one of claims 15 or 16.
20. The method according to claim 19, wherein said disorder or condition is selected from central or peripheral nervous system disorders, gastroesophogeal reflux disorder, gastrointestinal hypomotility disorders, irritable bowel syndrome, secretory diarrhea, asthma, cystic fibrosis, chronic obstructive pulmonary disease, rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, ischemia, cerebral ischemia, ischemic heart disease, angina pectoris, coronary heart disease, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, arrhythmia, hypertension, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.
21. The method according to claim 20, wherein said central or peripheral nervous system disorder comprises migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety, traumatic brain injury, dysmenorrhea, narcolepsy and motor neuron diseases.
22. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of one of claims 1-14 or a metal complex of one of claims 15 or 16.
PCT/US2005/012696 2004-04-13 2005-04-13 Polycyclic pyrimidines as potassium ion channel modulators WO2005099711A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP05749983A EP1742634B1 (en) 2004-04-13 2005-04-13 Polycyclic pyrimidines as potassium ion channel modulators
AT05749983T ATE485824T1 (en) 2004-04-13 2005-04-13 POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS
JP2007508533A JP2007532669A (en) 2004-04-13 2005-04-13 Polycyclic pyrimidines as potassium ion channel modulators
CA002561895A CA2561895A1 (en) 2004-04-13 2005-04-13 Polycyclic pyrimidines as potassium ion channel modulators
DE602005024382T DE602005024382D1 (en) 2004-04-13 2005-04-13 POLYCYCLIC PYRIMIDINES AS CALIUMIONAL CHANNEL MODULATORS
AU2005232745A AU2005232745A1 (en) 2004-04-13 2005-04-13 Polycyclic pyrimidines as potassium ion channel modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56199004P 2004-04-13 2004-04-13
US60/561,990 2004-04-13

Publications (1)

Publication Number Publication Date
WO2005099711A1 true WO2005099711A1 (en) 2005-10-27

Family

ID=34969928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/012696 WO2005099711A1 (en) 2004-04-13 2005-04-13 Polycyclic pyrimidines as potassium ion channel modulators

Country Status (8)

Country Link
US (1) US7560464B2 (en)
EP (1) EP1742634B1 (en)
JP (2) JP2007532669A (en)
AT (1) ATE485824T1 (en)
AU (1) AU2005232745A1 (en)
CA (1) CA2561895A1 (en)
DE (1) DE602005024382D1 (en)
WO (1) WO2005099711A1 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058392A1 (en) * 2005-11-21 2007-05-24 Japan Tobacco Inc. Heterocyclic compound and medicinal application thereof
EP1878733A1 (en) * 2006-07-14 2008-01-16 Novartis AG Pyrimidine derivatives as ALK-5 inhibitors
WO2009087224A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
WO2009119528A1 (en) * 2008-03-24 2009-10-01 武田薬品工業株式会社 Heterocyclic compound
WO2010026087A1 (en) * 2008-09-02 2010-03-11 Neurosearch A/S Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
WO2010026094A1 (en) * 2008-08-26 2010-03-11 Basf Se Detection and use of low molecular-weight modulators of the cold-menthol receptor trpm8
WO2010055114A1 (en) * 2008-11-14 2010-05-20 Bayer Cropscience Sa Substituted (pyridyl)-azinylamine derivatives as plant protection agents
WO2010057833A1 (en) * 2008-11-21 2010-05-27 Biomarin Iga, Ltd. Compounds for treatment of duchenne muscular dystrophy
US7855194B2 (en) 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
EP2521549A1 (en) * 2009-12-31 2012-11-14 Otsuka Pharmaceutical Co., Ltd. Therapeutic compounds and related methods of use
WO2013047719A1 (en) * 2011-09-30 2013-04-04 アステラス製薬株式会社 2-(pyridine-2-yl)pyrimidine-4-amine compound and salt thereof
US20140031547A1 (en) * 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
US8697715B2 (en) 2012-03-01 2014-04-15 Array Biopharma, Inc. Serine/threonine kinase inhibitors
US8778951B2 (en) 2009-07-30 2014-07-15 Novartis Ag Heteroaryl compounds and their uses
US8865894B2 (en) 2012-02-24 2014-10-21 Novartis Ag Oxazolidin-2-one compounds and uses thereof
US8957068B2 (en) 2011-09-27 2015-02-17 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US9133187B2 (en) 2011-02-28 2015-09-15 Array Biopharma Inc. Serine/threonine kinase inhibitors
EP2473486B1 (en) 2009-09-02 2015-10-28 Vifor (International) Ag Pyrimidines as hepcidine antagonists
US9187462B2 (en) 2011-08-04 2015-11-17 Array Biopharma Inc. Substituted quinazolines as serine/threonine kinase inhibitors
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
US9388171B2 (en) 2012-08-27 2016-07-12 Genetech, Inc. Serine/threonine kinase inhibitors
US9434719B2 (en) 2013-03-14 2016-09-06 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US9718839B2 (en) 2009-11-20 2017-08-01 Symrise Ag Use of physiological cooling active ingredients, and agents containing such active ingredients
EP2991977B1 (en) * 2013-05-01 2020-07-22 F.Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
US11434220B2 (en) 2017-08-31 2022-09-06 Basf Se Use of physiological cooling active ingredients, and compositions comprising such active ingredients
WO2023027517A1 (en) * 2021-08-27 2023-03-02 Yuhan Corporation 6-membered heteroaryl-containing aminopyridine compounds as egfr inhibitors

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2601527A1 (en) * 2005-03-14 2006-09-21 Neurosearch A/S Potassium channel modulating agents and their medical use
JP5607241B2 (en) 2010-05-21 2014-10-15 ケミリア・エービー New pyrimidine derivatives
WO2012127032A1 (en) 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives
CN103814030A (en) 2011-09-22 2014-05-21 辉瑞大药厂 Pyrrolopyrimidine and purine derivatives
TW202317106A (en) 2021-08-27 2023-05-01 南韓商柳韓洋行 Substituted aminopyridine compounds as egfr inhibitors

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1271116B (en) * 1965-05-04 1968-06-27 Bayer Ag Process for the preparation of 4-hydroxypyrimidines
EP0431421A2 (en) * 1989-12-07 1991-06-12 Bayer Ag Heteroarylsubstituted pyridinylpyrimidin derivatives
WO1995019358A1 (en) * 1994-01-12 1995-07-20 Sandoz Ltd. Herbicidal aryl and heteroaryl pyrimidines
WO2000039101A1 (en) * 1998-12-24 2000-07-06 Astrazeneca Ab Pyrimidine compounds
WO2000051987A2 (en) * 1999-03-05 2000-09-08 Kansas University Medical Center Inhibitors of advanced, post-amadori glycosylation reactions
WO2002047690A1 (en) * 2000-12-12 2002-06-20 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2002066036A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
WO2003027100A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl pyrimidines as c17,20 lyase inhibitors
WO2003077656A1 (en) * 2002-03-15 2003-09-25 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
WO2003094861A2 (en) 2002-05-13 2003-11-20 Icagen, Inc. Bis-benzimidazoles and related compounds as potassium channel modulators
WO2004039934A1 (en) * 2002-10-30 2004-05-13 Ciba Specialty Chemicals Holding Inc. Use of metal complex compounds as oxidation catalysts
WO2004065378A1 (en) * 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US5958934A (en) 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
US5952331A (en) 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
AT411372B (en) 2000-07-17 2003-12-29 Wiesner Erich Dr COMPONENT AND METHOD FOR THE PRODUCTION THEREOF

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1271116B (en) * 1965-05-04 1968-06-27 Bayer Ag Process for the preparation of 4-hydroxypyrimidines
EP0431421A2 (en) * 1989-12-07 1991-06-12 Bayer Ag Heteroarylsubstituted pyridinylpyrimidin derivatives
WO1995019358A1 (en) * 1994-01-12 1995-07-20 Sandoz Ltd. Herbicidal aryl and heteroaryl pyrimidines
WO2000039101A1 (en) * 1998-12-24 2000-07-06 Astrazeneca Ab Pyrimidine compounds
WO2000051987A2 (en) * 1999-03-05 2000-09-08 Kansas University Medical Center Inhibitors of advanced, post-amadori glycosylation reactions
WO2002047690A1 (en) * 2000-12-12 2002-06-20 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2002066036A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
WO2003027100A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl pyrimidines as c17,20 lyase inhibitors
WO2003077656A1 (en) * 2002-03-15 2003-09-25 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
WO2003094861A2 (en) 2002-05-13 2003-11-20 Icagen, Inc. Bis-benzimidazoles and related compounds as potassium channel modulators
WO2004039934A1 (en) * 2002-10-30 2004-05-13 Ciba Specialty Chemicals Holding Inc. Use of metal complex compounds as oxidation catalysts
WO2004065378A1 (en) * 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
ACKERMAN ET AL., NEW ENGL. J MED., vol. 336, 1997, pages 1575 - 1595
ADELMAN ET AL., NEURON, vol. 9, 1992, pages 209 - 216
ATKINSON ET AL., SCIENCE, vol. 253, 1991, pages 551 - 555
BERGE ET AL.: "Pharmaceutical Salts", JOURNAL OFPHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 1 - 19
BLATZ ET AL., NATURE, vol. 323, 1986, pages 718 - 720
BUTLER, SCIENCE, vol. 261, 1993, pages 221 - 224
CAO ET AL., JPHARMACOL. EXP. THER., vol. 296, 2001, pages 683 - 689
CAO; HOUAMED, FEBS LETT., vol. 446, 1999, pages 137 - 41
DANIEL ET AL., J PHARMACOL. METH., vol. 25, 1991, pages 185 - 193
DREIXLER ET AL., EUR. J. PHARMACOL., vol. 401, 2000, pages 1 - 7
HAMIL ET AL., PFLUGERS. ARCHIV., vol. 391, 1981, pages 85
HEINEMANN ET AL., J PHYSIOL., vol. 493, 1996, pages 625 - 633
HOLEVINSKY ET AL., J MEMBRANE BIOLOGY, vol. 137, 1994, pages 59 - 70
LATORRE ET AL., ANN. REV. PHYS., vol. 51, 1989, pages 385 - 399
MEERA ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 94, no. 25, 1997, pages 14066 - 14071
PARK, J PHYSIOL., vol. 481, 1994, pages 555 - 570
SANGUINETTI ET AL., NATURE, vol. 384, 1996, pages 80 - 83
SCHREIBER ET AL., J BIOL. CHEM., vol. 273, 1998, pages 3509 - 3516
SHAH ET AL., BRJPHARMACOL, vol. 129, 2000, pages 627 - 30
SHI ET AL., NEURON, vol. 16, no. 4, 1996, pages 843 - 852
SPICKETT R G W ET AL: "QUATERNARY SALTS FROM 2-CHLORO-5-NITROPYRIMIDINES. PART I. PREPARATION AND SOME REACTIONS", JOURNAL OF THE CHEMICAL SOCIETY. ABSTRACTS, XX, XX, 1955, pages 4354 - 4359, XP009052261, ISSN: 0590-9791 *
VESTERGARRD-BOGIND ET AL., J MEMBRANE BIOL., vol. 88, 1988, pages 67 - 75
WEI ET AL., NEUROPHARMACOLOGY, vol. 35, no. 7, 1997, pages 805 - 829

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058392A1 (en) * 2005-11-21 2007-05-24 Japan Tobacco Inc. Heterocyclic compound and medicinal application thereof
US7855194B2 (en) 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
EP1878733A1 (en) * 2006-07-14 2008-01-16 Novartis AG Pyrimidine derivatives as ALK-5 inhibitors
CN101910153A (en) * 2008-01-11 2010-12-08 诺瓦提斯公司 Pyrimidines as kinase inhibitors
WO2009087224A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
AU2009203693B2 (en) * 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
US8431578B2 (en) 2008-01-11 2013-04-30 Novartis Ag Organic compounds
WO2009119528A1 (en) * 2008-03-24 2009-10-01 武田薬品工業株式会社 Heterocyclic compound
EP3115045A3 (en) * 2008-08-26 2017-05-17 Basf Se Detection and use of low molecular weight modulators of the cold menthol receptor trpm8
US9346823B2 (en) 2008-08-26 2016-05-24 Basf Se Detection and use of low molecular-weight modulators of the cold-menthol receptor TRPM8
WO2010026094A1 (en) * 2008-08-26 2010-03-11 Basf Se Detection and use of low molecular-weight modulators of the cold-menthol receptor trpm8
US8710096B2 (en) 2008-08-26 2014-04-29 Basf Se Detection and use of low molecular-weight modulators of the cold-menthol receptor TRPM8
CN107375284A (en) * 2008-08-26 2017-11-24 巴斯夫欧洲公司 The detection of cold menthol receptor TRPM8 low molecule amount conditioning agent and purposes
CN107375284B (en) * 2008-08-26 2020-08-07 巴斯夫欧洲公司 Detection and use of low molecular weight modulators of the cold menthol receptor TRPM8
US8618099B2 (en) 2008-09-02 2013-12-31 Ataxion, Inc. Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
CN102177154A (en) * 2008-09-02 2011-09-07 神经研究公司 Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
WO2010026087A1 (en) * 2008-09-02 2010-03-11 Neurosearch A/S Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
CN102216286A (en) * 2008-11-14 2011-10-12 拜尔农科股份公司 Substituted (pyridyl)-azinylamine derivatives as plant protection agents
WO2010055114A1 (en) * 2008-11-14 2010-05-20 Bayer Cropscience Sa Substituted (pyridyl)-azinylamine derivatives as plant protection agents
WO2010057833A1 (en) * 2008-11-21 2010-05-27 Biomarin Iga, Ltd. Compounds for treatment of duchenne muscular dystrophy
US8778951B2 (en) 2009-07-30 2014-07-15 Novartis Ag Heteroaryl compounds and their uses
EP2473486B1 (en) 2009-09-02 2015-10-28 Vifor (International) Ag Pyrimidines as hepcidine antagonists
US10584134B2 (en) 2009-11-20 2020-03-10 Symrise Ag Use of physiological cooling active ingredients, and agents containing such active ingredients
US9718839B2 (en) 2009-11-20 2017-08-01 Symrise Ag Use of physiological cooling active ingredients, and agents containing such active ingredients
CN102883723B (en) * 2009-12-31 2015-09-16 大塚制药株式会社 Therapeutic compound and relevant using method
CN102883723A (en) * 2009-12-31 2013-01-16 大塚制药株式会社 Therapeutic compounds and related methods of use
AU2010339423C1 (en) * 2009-12-31 2017-03-09 Otsuka Pharmaceutical Co., Ltd. Therapeutic compounds and related methods of use
AU2010339423B2 (en) * 2009-12-31 2016-12-01 Otsuka Pharmaceutical Co., Ltd. Therapeutic compounds and related methods of use
EP2521549A1 (en) * 2009-12-31 2012-11-14 Otsuka Pharmaceutical Co., Ltd. Therapeutic compounds and related methods of use
EP2521549A4 (en) * 2009-12-31 2013-06-05 Otsuka Pharma Co Ltd Therapeutic compounds and related methods of use
CN105218516A (en) * 2009-12-31 2016-01-06 大塚制药株式会社 Therapeutic compound and relevant using method
US9630947B2 (en) 2009-12-31 2017-04-25 Otsuka Pharmaceutical Co., Ltd. Therapeutic compounds and related methods of use
US9073890B2 (en) 2009-12-31 2015-07-07 Otsuka Pharmaceutical Co., Ltd. Therapeutic compounds and related methods of use
US9789111B2 (en) 2010-12-14 2017-10-17 Electrophoretics Limited Casein kinase 1δ (CK 1δ) inhibitors
US9763947B2 (en) 2010-12-14 2017-09-19 Electrophoretics Limited Casein kinase 1delta (CK1delta) inhibitors
US20140031547A1 (en) * 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
US9133187B2 (en) 2011-02-28 2015-09-15 Array Biopharma Inc. Serine/threonine kinase inhibitors
US9187462B2 (en) 2011-08-04 2015-11-17 Array Biopharma Inc. Substituted quinazolines as serine/threonine kinase inhibitors
US8957068B2 (en) 2011-09-27 2015-02-17 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
WO2013047719A1 (en) * 2011-09-30 2013-04-04 アステラス製薬株式会社 2-(pyridine-2-yl)pyrimidine-4-amine compound and salt thereof
US8865894B2 (en) 2012-02-24 2014-10-21 Novartis Ag Oxazolidin-2-one compounds and uses thereof
US9458177B2 (en) 2012-02-24 2016-10-04 Novartis Ag Oxazolidin-2-one compounds and uses thereof
US10519126B2 (en) 2012-03-01 2019-12-31 Array Biopharma Inc. Serine/threonine kinase inhibitors
US9708290B2 (en) 2012-03-01 2017-07-18 Array Biopharma Inc. Serine/threonine kinase inhibitors
US9259470B2 (en) 2012-03-01 2016-02-16 Array Biopharma Inc. Serine/threonine kinase inhibitors
US8697715B2 (en) 2012-03-01 2014-04-15 Array Biopharma, Inc. Serine/threonine kinase inhibitors
US9388171B2 (en) 2012-08-27 2016-07-12 Genetech, Inc. Serine/threonine kinase inhibitors
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
US10202371B2 (en) 2012-11-12 2019-02-12 Novartis Ag Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors
US10112931B2 (en) 2013-03-14 2018-10-30 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US9434719B2 (en) 2013-03-14 2016-09-06 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US9688672B2 (en) 2013-03-14 2017-06-27 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
EP2991977B1 (en) * 2013-05-01 2020-07-22 F.Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
US11434220B2 (en) 2017-08-31 2022-09-06 Basf Se Use of physiological cooling active ingredients, and compositions comprising such active ingredients
WO2023027517A1 (en) * 2021-08-27 2023-03-02 Yuhan Corporation 6-membered heteroaryl-containing aminopyridine compounds as egfr inhibitors

Also Published As

Publication number Publication date
CA2561895A1 (en) 2005-10-27
AU2005232745A1 (en) 2005-10-27
JP2007532669A (en) 2007-11-15
ATE485824T1 (en) 2010-11-15
US20050267089A1 (en) 2005-12-01
JP2008247916A (en) 2008-10-16
EP1742634B1 (en) 2010-10-27
DE602005024382D1 (en) 2010-12-09
EP1742634A1 (en) 2007-01-17
US7560464B2 (en) 2009-07-14

Similar Documents

Publication Publication Date Title
US7560464B2 (en) Polycyclic pyrimidines as potassium ion channel modulators
EP1742935B1 (en) Polycyclic pyrazines as potassium ion channel modulators
US20050227989A1 (en) Polycyclic thiazoles as potassium ion channel modulators
KR20070030196A (en) Polycyclic pyridines as potassium ion channel modulators
US7459457B2 (en) Polycyclic pyridines as potassium ion channel modulators
US7482373B2 (en) Bis-benzimidazoles and related compounds as potassium channel modulators
AU2008237721A1 (en) Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase
WO2002074388A1 (en) Bisarylamines as potassium channel openers
WO2005002503A2 (en) Asymmetric benzimidazoles and related compounds as potassium channel modulators
CN116870016A (en) Heteroaromatic compound and medical application thereof
EP1483259A1 (en) Pyrimidines as novel openers of potassium ion channels
CN117412981A (en) Phosphine oxide derivative and preparation method and application thereof
AU2002238023A1 (en) Pyridine-substituted benzanilides as potassium ion channel openers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2561895

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005232745

Country of ref document: AU

Ref document number: 2007508533

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005749983

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005232745

Country of ref document: AU

Date of ref document: 20050413

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005232745

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005749983

Country of ref document: EP